

(19) **DANMARK**

(10) **DK/EP 3750893 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 07 D 491/056 (2006.01)** **A 61 K 31/519 (2006.01)** **A 61 P 35/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2023-05-08**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2023-04-19**
- (86) Europæisk ansøgning nr.: **19751025.8**
- (86) Europæisk indleveringsdag: **2019-01-25**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-12-16**
- (86) International ansøgning nr.: **CN2019073260**
- (87) Internationalt publikationsnr.: **WO2019154133**
- (30) Prioritet: **2018-02-11 WO PCT/CN2018/076233** **2018-08-27 CN 201810983341**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Beijing Scitech-MQ Pharmaceuticals Limited, No.10 Lin He North Street , Shun Yi District, Beijing 101320, Kina**
- (72) Opfinder: **ZHANG, Qiang, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina**
YU, Shannan, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
WANG, Zhongxiang, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
FENG, Shouye, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
SUN, Yueming, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
LIU, Yansheng, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
ZHANG, Hongbo, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
YANG, Leifu, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
YANG, Hailong, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
ZHOU, Likai, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
ZHENG, Nanqiao, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
HU, Chenming, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
XU, Zhanqiang, No.10, Lin He North Street, Shunyi District, Beijing 101320, Kina
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **DIOXAZOLINFORBINDELSE, FREMGANGSMÅDE TIL FREMSTILLING DERAFF OG ANVENDELSER DERAFF**
- (56) Fremdragne publikationer:
WO-A1-2018/153293
WO-A1-2018/157730
CN-A- 103 328 447
CN-A- 103 402 505
CN-A- 104 530 063

Fortsættes ...

CN-A- 105 541 798
CN-A- 105 837 586

DESCRIPTION

TECHNICAL FIELD

[0001] The present disclosure relates to a dioxinoquinoline compound, or a pharmaceutically acceptable salt, an enantiomer or a diastereomer, a hydrate, or a solvate thereof, as well as the preparation method and use thereof.

BACKGROUND

[0002] Receptor tyrosine kinases (RTKs) cross cell membranes and affect the trans-cellular membrane transmission of biochemical signals. They are consisted of three parts: an extracellular domain containing a ligand binding site, a single transmembrane region, and an intracellular domain containing the activity of tyrosine protein kinase. The binding of a ligand to a receptor stimulates the activity of the relevant receptor tyrosine kinase, which leads to the phosphorylation of tyrosine residues on the receptor and other intracellular molecules, which in turn triggers cascade signals that cause various cellular responses. The overexpression of tyrosine receptor activates downstream signal transduction pathways, which ultimately leads to abnormal transformation and proliferation of cells, and promotes the occurrence and development of tumors.

[0003] A vascular endothelial growth factor receptor (VEGFR) is a member of the receptor tyrosine kinase family. It binds to its ligand, vascular endothelial growth factor (VEGF), to produce a series of biochemical and physiological processes, which ultimately promote the formation of new blood vessels. The formation and permeability of tumor blood vessels are mainly regulated by vascular endothelial growth factor (VEGF), which acts through at least two different receptors (VEGFR-1, VEGFR-2). According to studies by Jakeman, Kolch, Connolly, etc., VEGF is an important stimulus for normal and pathological angiogenesis and vascular permeability (Jakeman et al., 1993, *Endocrinology* 133: 848-859; Kolch et al., 1995, *Breast Cancer Research and Treatment*, 36:139-155; Connolly et al., 1989, *J. Biol. Chem.* 264: 20017-20024). Vascular endothelial cell growth factor induces vascular sprouting phenotype by inducing endothelial cell proliferation, protease expression, and migration of cell tissues that subsequently form capillary. Therefore, the antagonism of VEGF produced by the chelation of VEGF by antibodies can lead to the inhibition of tumor growth (Kim et al., 1993, *Nature* 362: 841-844).

[0004] Because VEGFR-2 is mainly distributed in vascular endothelial cells, it can bind to VEGF-A, VEGF-C, VEGF-D, and VEGF-E. However, the effects of VEGF on stimulating endothelial cell proliferation, increasing the permeability of blood vessels and increasing the formation of new blood vessels are mainly achieved by binding and activating VEGFR-2. If the activity of VEGFR-2 is blocked, the growth and metastasis of tumors can be inhibited through

direct and indirect pathways, thereby achieving ideal anti-tumor effect. Therefore, the search for small molecular inhibitors with high activity and high selectivity for VEGFR-2 has become a very promising strategy for the tumor treatment.

[0005] A hepatocyte growth factor receptor (c-MET) is a kind of tyrosine kinase receptors, the abnormal activation of which plays an important role in the occurrence and development of various malignant tumors including lung cancer. A hepatocyte growth factor (HGF) is a specific ligand for c-MET, and c-MET binds to HGF to play a biological role through HGF/c-MET signaling pathway. The HGF/c-MET signaling pathway can induce a series of biological effects such as cell proliferation, dispersion, migration, organ morphogenesis, and angiogenesis. Abnormal activation of c-MET can manifest as receptor overexpression, gene mutation, amplification, translocation, rearrangement, etc. These changes can lead to dysregulation of downstream signaling pathways, such as serine/threonine protein kinase (AKT), extracellular signaling kinase (ERK), phosphatidylinositol-3-hydroxykinase, and retinoblastoma inhibitory protein (Rb), thereby mediating processes such as tumorigenesis, invasion and metastasis, angiogenesis, and epithelial-mesenchymal transition. c-MET plays an important role in cell proliferation, metabolism, tumor generation, metastasis, and angiogenesis, and has become an important target for the anti-tumor therapy. Targeted therapy with c-MET as the target has shown great significance in the treatment of various malignant tumors including lung cancer.

[0006] During the treatment with anti-tumor drugs, the interaction of multiple signaling pathways will affect the effect of anti-tumor drugs. For example, the interaction of the HGF/c-MET signaling pathway with other pathways affects the therapeutic effect of anti-tumor drugs and produces drug resistance. Therefore, drug combination against multiple kinase targets has become a new anti-tumor therapy. Moreover, the successful marketing of Crizotinib and Cabozantinib shows that the development of inhibitors for multiple kinase targets has good potential and application value.


[0007] Cabozantinib is a small molecular inhibitor of protein kinase, which can inhibit c-MET, VEGFR-2, Ret, Kit, AXL and other kinases. Cabozantinib can inhibit the phosphorylation of c-MET and VEGFR-2 in tumor models, and shows effective activity of anti-tumor metastasis and anti-angiogenesis in preclinical drug efficacy models. Compared with an inhibitor that acts on VEGFR target alone, no increase in tumor burden was found in the lung tumor metastasis model treated with Cabozantinib, indicating that Cabozantinib is an effective inhibitor of tumor angiogenesis and metastasis in tumor patients with dysregulated c-MET and VEGFR-2 signaling pathways. The FDA approved the marketing of Cabozantinib on November 29, 2012 for the treatment of patients with progressive, metastatic medullary thyroid carcinoma (MTC). Further reference is made to EP3246328.

[0008] Inhibitors like Cabozantinib that act on multiple targets have many advantages, and thus there are many researches on this type of inhibitor. At present, there are few such drugs on the market, the drug availability is limited, and the drugs that have been marketed encounter problems such as drug resistance and side effects during use. Therefore, compared with marketed inhibitors against single target, small molecular inhibitors for multiple targets will

have better therapeutic effects and application prospects.

SUMMARY

[0009] The present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt, an enantiomer or a diastereomer, a hydrate, or a solvate thereof, which can be used to treat or prevent diseases caused by tyrosine kinases (e.g., VEGFR-2 and/or c-MET), including some variants of tyrosine kinase receptors,




Formula (I)
in the formula (I),

Q is CH;

G is O;

Z is CH;

L is selected from the group consisting of



, wherein X is H or C₁-C₃ alkyl; Y is H or C₁-C₃ alkyl; n is 0 to 3, and when n is 0, L represents



R¹ is H, C₁-C₉ alkyl, C₃-C₇ cycloalkyl, 4- to 7-membered heterocyclyl, C₁-C₆ alkyl substituted with C₃-C₇ cycloalkyl, C₁-C₆ alkyl substituted with 4- to 7-membered heterocyclyl, or C₁-C₉ alkyl substituted with one or more of the following: hydroxyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio and -NR⁶R⁷,

R⁶ and R⁷ are each independently H, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with hydroxyl, or C₁-C₆ alkyl substituted with C₁-C₃ alkoxy;

the above 4- to 7-membered heterocyclyl is a 4- to 7-membered heterocyclyl containing 1 to 2 atoms selected from the group consisting of N, O, and S, which is unsubstituted, or is substituted with C₁-C₃ alkyl or C₁-C₃ acyl, or is oxidized by 1 to 2 oxygen atoms;

R² is H, C₁-C₃ alkyl or halogen;

R³ is H, C₁-C₃ alkyl or halogen;

R⁴ is H, C₁-C₃ alkyl or halogen;

R⁵ is H, C₁-C₉ alkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkyl substituted with C₃-C₇ cycloalkyl, aryl, C₁-C₆ alkyl substituted with aryl, heteroaryl, or C₁-C₆ alkyl substituted with heteroaryl;

the aryl and heteroaryl are unsubstituted, or substituted with one or more of the following: C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkylthio, amino substituted with mono- or di-C₁-C₃ alkyl, halogen, trifluoromethyl, aryloxy and methylsulfonyl; and

the heteroaryl is a monocyclic or bicyclic group containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and containing 5 to 10 ring atoms.

[0010] According to an alternative embodiment, R¹ is H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, 5- to 6-membered heterocyclyl, C₁-C₃ alkyl substituted with C₃-C₆ cycloalkyl, C₁-C₃ alkyl substituted with 5- to 6-membered heterocyclyl, or C₁-C₆ alkyl substituted with the following: hydroxyl, C₁-C₃ alkoxy, C₁-C₃ alkylthio or -NR⁶R⁷,

R⁶ and R⁷ are each independently -H, C₁-C₃ alkyl, C₁-C₃ alkyl substituted with hydroxyl, or C₁-C₃ alkyl substituted with C₁-C₃ alkoxy; and

the above 5- to 6-membered heterocyclyl is a 5- to 6-membered heterocyclyl containing 1 to 2 atoms selected from the group consisting of N, O, and S, which is unsubstituted, or is substituted with C₁-C₃ alkyl or C₁-C₃ acyl, or is oxidized by 1 to 2 oxygen atoms.

[0011] According to an alternative embodiment, R¹ is selected from the group consisting of one or more of the following: methyl, ethyl, propyl, isopropyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, tetrahydropyrrol-1-ylethyl, tetrahydropyrrol-1-ylpropyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, piperazin-1-ylethyl, piperazin-1-ylpropyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, methylpiperazin-4-ylethyl, methylpiperazin-4-ylpropyl, N-formylpiperazin-4-ylethyl, N-formylpiperazin-4-ylpropyl, N-acetylpiperazin-4-ylethyl, N-acetylpiperazin-4-ylpropyl, (1,1-dioxothiomorpholin)-4-ylethyl, (1,1-dioxothiomorpholin)-4-ylpropyl, methylthioethyl, methylthiopropyl, dimethylaminoethyl, dimethylaminopropyl, dimethylaminobutyl, dimethylaminopentyl, dimethylaminohexyl, diethylaminoethyl, diethylaminopropyl, hydroxyethyl, hydroxypropyl, hydroxyethylaminoethyl, hydroxypropylaminoethyl, hydroxyethylaminopropyl, methoxyethylaminoethyl, methoxypropylaminoethyl, methoxyethylaminopropyl, aminoethyl, aminopropyl, aminobutyl, N-methyl-N-hydroxyethylaminoethyl, N-methyl-N-

hydroxypropylaminoethyl, N-methyl-N-hydroxyethylaminopropyl, N-methyl-N-methoxyethylaminoethyl, N-methyl-N-methoxypropylaminoethyl, N-methyl-N-methoxyethylaminopropyl, 2-methyl-2-hydroxypropyl, 3-methyl-3-hydroxybutyl, (3S)-3-aminobutyl, (3R)-3-aminobutyl, (3S)-3-hydroxybutyl or (3R)-3-hydroxybutyl.


[0012] According to an alternative embodiment, R^1 is selected from the group consisting of butyl, isobutyl, pentyl, isopentyl, hexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, 4,4-dimethylpiperidin-1-ylethyl, 4,4-dimethylpiperidin-1-ylpropyl, and oxetan-3-yl.

[0013] According to an alternative embodiment, the halogen described in R^2 , R^3 , and R^4 is Cl or F.

[0014] According to an alternative embodiment, R^5 is -H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkyl substituted with C_3 - C_6 cycloalkyl, aryl, C_1 - C_3 alkyl substituted with aryl, heteroaryl, or C_1 - C_3 alkyl substituted with heteroaryl, wherein the aryl and heteroaryl are substituted with one or more of the following: C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 alkylthio, amino substituted with mono- or di- C_1 - C_3 alkyl, halogen, trifluoromethyl, aryloxy and methylsulfonyl; and the heteroaryl is a monocyclic or bicyclic group containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S, and containing 5 to 10 ring atoms.

[0015] Yet alternatively, R^5 is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, 4-fluorophenyl, 3-fluorophenyl, 2-fluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2-fluoro-4-(trifluoromethyl)phenyl, 2-fluoro-5-(trifluoromethyl)phenyl, 3-fluoro-4-(trifluoromethyl)phenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 3-(trifluoromethyl)-4-fluorophenyl, 2-fluoro-4-chlorophenyl, 2-fluoro-5-chlorophenyl, 3-fluoro-4-chlorophenyl, 3-fluoro-5-chlorophenyl, 3-chloro-4-fluorophenyl, 2-chloro-4-(trifluoromethyl)phenyl, 2-chloro-5-(trifluoromethyl)phenyl, 3-chloro-4-(trifluoromethyl)phenyl, 3-chloro-5-(trifluoromethyl)phenyl, 3-(trifluoromethyl)-4-chlorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-5-fluorophenyl, 3-chloro-4-fluorophenyl, benzyl, phenethyl, 4-fluorobenzyl, naphthalen-1-yl, 3-methyl-isoxazol-5-yl, 4-phenoxyphenyl, 3-(methylsulfonyl)phenyl, 4-(methylsulfonyl)phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 3-methoxybenzyl or 4-methoxybenzyl.

[0016] The present application also provides a compound of formula (I), or a pharmaceutically acceptable salt, an enantiomer or a diastereomer, a hydrate, or a solvate thereof




Formula (I)
in the formula (I),

Q is CH;

G is O;

Z is CH;

L is selected from the group consisting of



wherein X is H or C₁-C₃ alkyl; Y is H or C₁-C₃ alkyl; n is 0 to 3, and when n is 0, L represents



R¹ is C₁-C₆ alkyl substituted with 1 to 3 substituents selected from the group consisting of C₁-C₃ acyl, halogen, trifluoromethyl, cyano, -CONH₂, -NR^aR^b and 4- to 7-membered heteroalicyclic group, wherein the 4- to 7-membered heteroalicyclic group is a 4- to 7-membered heteroalicyclic group containing 1 to 2 atoms selected from the group consisting of N, O, and S as ring atoms, and the 4- to 7-membered heteroalicyclic group is substituted with 1 to 3 substituents selected from the group consisting of halogen, C₁-C₃ alkyl, hydroxyl, -NH₂, and C₁-C₃ acyl,

R^a and R^b are each independently -H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkyl substituted with C₁-C₃ alkoxy, C₁-C₆ alkyl substituted with C₁-C₃ alkylthio, C₁-C₆ alkyl substituted with substituted amino or unsubstituted amino, wherein the substituted amino is substituted with mono- or di-C₁-C₃ alkyl;

R², R³, and R⁴ are each independently H, C₁-C₃ alkyl or halogen;

R⁵ is -H, C₁-C₉ alkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkyl substituted with C₃-C₇ cycloalkyl, aryl, C₁-C₆ alkyl substituted with aryl, heteroaryl, or C₁-C₆ alkyl substituted with heteroaryl;

the aryl and heteroaryl are unsubstituted, or are substituted with 1 to 3 substituents selected from the group consisting of one or more of the following: hydroxyl, amino, cyano, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃ alkylthio, amino substituted with mono- or di-C₁-C₃ alkyl, halogen, trifluoromethyl, and methylsulfonyl; and

the above heteroaryl is a monocyclic or bicyclic group containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S and containing 5 to 10 ring atoms.

[0017] According to an alternative embodiment, R^1 is C_1 - C_6 alkyl substituted with 1 to 3 substituents selected from the group consisting of C_1 - C_3 acyl, -F, trifluoromethyl, cyano, -CONH₂, -NR^aR^b and 4- to 7-membered heteroalicyclic group, wherein the 4- to 7-membered heteroalicyclic group is a 4- to 7-membered heteroalicyclic group containing 1 to 2 atoms selected from the group consisting of N, O, and S as ring atoms, and the 4- to 7-membered heteroalicyclic group is substituted with 1 to 3 substituents selected from the group consisting of -F, C_1 - C_3 alkyl, hydroxyl, -NH₂, and C_1 - C_3 acyl,


R^a and R^b are each independently -H, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 alkyl substituted with C_1 - C_3 alkoxy, C_1 - C_3 alkyl substituted with C_1 - C_3 alkylthio, C_1 - C_3 alkyl substituted with substituted amino or unsubstituted amino, wherein the substituted amino is substituted with mono- or di- C_1 - C_3 alkyl;

R^2 , R^3 and R^4 are each independently -H, -F or -Cl;

R^5 is -H, aryl, C_1 - C_3 alkyl substituted with aryl, heteroaryl, or C_1 - C_3 alkyl substituted with heteroaryl, wherein the aryl and heteroaryl are unsubstituted, or are substituted with 1 to 3 substituents selected from the group consisting of one or more of the following: hydroxyl, amino, cyano, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 alkylthio, amino substituted with mono- or di- C_1 - C_3 alkyl, halogen, trifluoromethyl and methylsulfonyl; and

the heteroaryl is a monocyclic or bicyclic group containing 5 to 10 ring atoms and containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S.

[0018] Yet alternatively, R^1 is selected from the group consisting of cyanomethyl, cyanoethyl, cyanopropyl, -CH₂CONH₂, -CH₂CF₃,




4-methyl-4-hydroxypiperidin-1-ylpropyl, 4-methyl-4-hydroxypiperidin-1-ylethyl, 4-methyl-4-aminopiperidin-1-ylpropyl, 4-methyl-4-aminopiperidin-1-ylethyl, N-methyl-N-cyclobutylaminopropyl, N-methyl-N-cyclopropylaminopropyl, N-methyl-N-cyclopentylaminopropyl, N-methyl-N-cyclohexylaminopropyl, N-methyl-N-cyclobutylaminoethyl, N-methyl-N-cyclopropylaminoethyl, N-methyl-N-cyclopentylaminoethyl, and N-methyl-N-cyclohexylaminoethyl.


[0019] The present disclosure provides a pharmaceutically acceptable salt of the compound of formula (I), wherein the salt is an acidic/anionic salt or a basic/cationic salt; the pharmaceutically acceptable acidic/anionic salt usually takes the form of protonating basic nitrogen(s) in them with inorganic or organic acids. Representative organic or inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, perchloric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, succinic

acid, maleic acid, tartaric acid, malic acid, citric acid, fumaric acid, gluconic acid, benzoic acid, mandelic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, oxalic acid, palmitic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, salicylic acid, hexonic acid, trifluoroacetic acid. Pharmaceutically acceptable basic/cationic salts include but are not limited to salts of aluminum, calcium, chlorprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.


[0020] The present disclosure provides a method of preparing the above compound or a pharmaceutically acceptable salt, an enantiomer or a diastereomer, a hydrate, or a solvate thereof, characterized in that the method includes the step of reacting the compound of formula (II') with the compound of formula (III') to afford the compound of formula (I), wherein Q, G, Z, L, R¹, R², R³, R⁴ and R⁵ are as defined above,



[0021] The present disclosure provides a method of preparing the above compound or a pharmaceutically acceptable salt, an enantiomer or a diastereomer, a hydrate, or a solvate thereof, characterized in that the method includes the step of reacting the compound of formula (II') with the compound of formula (III) to afford the compound of formula (I), wherein Q, G, Z, L, R¹, R², R³, R⁴ and R⁵ are as defined above,



[0022] The present disclosure provides an intermediate for preparing the above compound, i.e., a compound of formula (II'), wherein Q, G, Z, R¹, R², R³, and R⁴ are as defined above,



DETAILED DESCRIPTION OF THE EMBODIMENTS

[0023] Unless otherwise stated, the following terms used in this application (including the specification and claims) have the definitions given below. In this application, the use of "or" or "and" means "and/or" unless stated otherwise. In addition, the use of the term "comprising" and other forms such as "including", "containing" and "having" is not limiting. The chapter headings used herein are for organizational purposes only and should not be interpreted as limitations on the topics described.

[0024] The term "substituted" as used herein, includes multiple substituents (e.g., phenyl, aryl, heteroalkyl, heteroaryl), preferably 1 to 5 substituents, more preferably 1 to 3 substituents, most preferably 1 or 2 substituents, independently selected from the list of substituents.

[0025] Unless otherwise specified, alkyl includes saturated linear and branched hydrocarbon group, C₁-C₉ represents the number of carbon atoms of an alkyl is 1-9. Similarly, for example, C₁-C₃ represents the number of carbon atoms of an alkyl is 1-3, e.g., C₁-C₆ alkyl includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl, and 2-methylpentyl, etc. An alkoxy group is an alkyl-O- group formed from a linear or branched alkyl group described previously and -O-. Similarly, alkenyl and alkynyl groups include linear or branched alkenyl or alkynyl groups.

[0026] Cycloalkyl refers to a cyclic group formed by carbon atoms. For example, C₃-C₇ cycloalkyl may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Similarly, cyclic alkenyl group is also included herein.

[0027] The term "aryl" as used herein, unless otherwise specified, refers to an unsubstituted or substituted aromatic group, such as phenyl, naphthyl, anthracenyl.

[0028] "Oxidized by one or two oxygen atoms" refers to a sulfur atom oxidized by one oxygen atom to form a double bond between the sulfur and oxygen, or oxidized by two oxygen atoms to form double bonds between the sulfur and two oxygen atoms.

[0029] The term "heterocyclyl" as used herein, unless otherwise specified, represents an unsubstituted or substituted stable 3 to 8 membered monocyclic saturated ring system consisting of carbon atoms and 1 to 3 heteroatoms selected from N, O, and S, wherein the N, S heteroatoms can be optionally oxidized, and the N heteroatoms can also be optionally quaternized. Examples of such heterocyclyl rings include, but are not limited to, azetidiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, dioxolanyl, dioxanyl, tetrahydroimidazolyl, tetrahydrooxazolyl, thiamorpholinyl sulfoxide, thiomorpholine sulfone and oxadiazolyl.

[0030] The term "heteroaryl" as used herein, unless otherwise specified, represents an unsubstituted or substituted stable 5 or 6 membered monocyclic aromatic ring system, and may also represent unsubstituted or substituted 9 or 10-membered benzo-fused


heteroaromatic ring system or a bicyclic heteroaromatic ring system consisting of carbon atoms and one to three heteroatoms selected from N, O, S, wherein the N, S heteroatoms may optionally be oxidized, and N heteroatoms may optionally be quaternized. Heteroaryl can be attached at any heteroatom or carbon atom to form a stable structure. Heteroaryl includes but is not limited to thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, pyranlyl, pyridinyl, piperazinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, thiadiazolyl, triazolyl, indolyl, azaindolyl, indazolyl, azaindazolyl, benzimidazolyl, benzofuryl, benzothienyl, benzoisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, adeninyl, quinolinyl, or isoquinolinyl.

[0031] The term "carbonyl" refers to a -C(O)- group.

[0032] Whenever the terms "alkyl" or "aryl" or either of their prefix roots appear in the name of a substituent (eg, aralkyl, dialkylamino), it shall be interpreted to contain those limitations given for the above "alkyl" and "aryl". Designated numbers of carbon atoms (e.g., C₁-C₆) shall independently represent the number of carbon atoms in an alkyl moiety or an alkyl moiety in a larger substituent (wherein the alkyl group is the prefix root).


[0033] The present disclosure also provides methods for preparing corresponding compounds. Various synthetic methods can be used to prepare the compounds described herein, including the following methods. The compound disclosed herein or a pharmaceutically acceptable salt, an enantiomer or a diastereomer, or a hydrate thereof can be synthesized using the following methods and synthetic methods known in the field of organic chemical synthesis, or by variations of these methods as understood by those skilled in the art. Preferred methods include, but are not limited to, the following methods.

[0034] In one embodiment, the compound of formula (I) disclosed herein is prepared by reacting the compound of formula (II') with the compound of formula (III') or formula (III), wherein Q, G, Z, L, R¹, R², R³, R⁴ and R⁵ are as described above.




[0035] The present disclosure further provides an intermediate for preparing the compound of formula (I), i.e., a compound of formula (II'), wherein Q, G, Z, R¹, R², R³, and R⁴ are as defined

above,



[0036] The compounds disclosed herein can be prepared by the following methods or by technical solutions known to those skilled in the art,



[0037] Step 1) A nitration reaction is carried out, preferably, with nitric acid and acetic acid.

[0038] Step 2) A nitro-reduction reaction is carried out by routine operations known by those skilled in the art;

preferably, the conditions of the nitro-reduction reaction include, but are not limited to, hydrogen and Raney nickel, hydrogen and palladium/carbon, an iron or zinc powder under an acidic condition, or stannous chloride.

[0039] Step 3) 1-(8-methoxy-6-amino-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one and methyl formate or ethyl formate are reacted in an organic solvent, and catalyzed by a base to afford 10-hydroxy-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline, wherein the organic solvent includes, but is not limited to, one or a combination of two or more of dioxane, tetrahydrofuran, t-butanol, ethanol, and methanol; the base includes, but is not limited to, sodium t-butoxide, potassium t-butoxide, sodium methoxide, and sodium ethoxide; and this reaction can also be carried out under heating with the temperature of from room temperature to reflux temperature.

[0040] Step 4) 10-hydroxy-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline is reacted with a chlorinating reagent in an organic solvent to afford 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline, wherein the chlorinating reagent is phosphorus oxychloride; the organic solvent includes, but is not limited to, one or a combination of two or more of benzene, toluene, chlorobenzene and xylene; and the reaction can also be carried out in the presence of an organic base, e.g., triethylamine or diisopropylethylamine.

[0041] Step 4a) 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline is dissolved in an organic solvent and subjected to the action of Lewis acid to afford 5-hydroxy-10-chloro-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline, wherein the Lewis acid is boron tribromide or boron trichloride; and the organic solvent is dichloromethane.

[0042] Step 4b) 5-hydroxy-10-chloro-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline is reacted with the compound of R^1X in an organic solvent to afford the compound of formula III-A, wherein R^1 is as defined above; the organic solvent includes, but is not limited to, one or a combination of two or more of tetrahydrofuran, dioxane, DMF, DMA, DMSO, and acetonitrile; X in R^1X is chlorine, bromine, iodine, mesylate, p-toluenesulfonate or triflate.

[0043] Step 5) The compound of formula III-A was dissolved in an organic solvent, mixed with the compound of formula V', and heated to 100°C to 140°C to afford the compound of IV'; wherein the organic solvent is selected from the group consisting of one or a combination of two or more of toluene, chlorobenzene, xylene, DMF, DMA and DMSO.

[0044] Step 6) A nitro-reduction reaction is carried out by routine operations known by those skilled in the art; preferably, the conditions of the nitro-reduction reaction include, but are not limited to, hydrogen and Raney nickel, hydrogen and palladium/carbon, an iron or zinc powder under an acidic condition, or stannous chloride.

[0045] Step 7) In an alternative embodiment, when the compound of formula (III') is reacted with the compound of formula (II'-A), the compound of formula (III') can be first reacted with an acylating reagent, and then reacted with the compound of formula (II'-A).

[0046] Preferably, the acylating reagent includes, but is not limited to, one or a combination of two or more of phosphorus oxychloride, thionyl chloride, oxalyl chloride, phosphorus trichloride, or phosphorus pentachloride.

[0047] In another embodiment, the compound of formula (III') is reacted with the compound of formula (II'-A) in the presence of a condensing agent to afford the compound of formula (I-C),

preferably, the condensing agent includes, but is not limited to, one or a combination of two or more of carbodiimide-based condensing agent, onium salt-based condensing agent, organic phosphorus-based condensing agent and other types of condensing agents, preferably N,N'-

dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), 1-hydroxybenzotriazole (HOBt), N,N-diisopropylethylamine (DIEA), 1-hydroxy-7-azabenzotriazole (HOAt), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), propylphosphonic anhydride (T3P), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and (3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP);

preferably, this step can be carried out in an organic base, which includes, but is not limited to, one or a combination of two or more of triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, 2,6-lutidine, 1,8-diazabicycloundec-7-ene or N-methylmorpholine.

[0048] When R¹ is -CH₃, steps 4a and 4b can be omitted. That is to say, after completing step 4), the operation of step 5) is carried out.

[0049] Meanwhile, for example, the order of steps 4a and 4b and step 5 may not be fixed. For example, step 5 may be first carried out, followed by steps 4a and 4b.

[0050] It is apparent that the compounds of Formula I, the isomers, crystalline forms or prodrugs, and pharmaceutically acceptable salts thereof, may exist in both solvated and unsolvated forms. For example, the solvated form can be a hydrate form. The disclosure includes both solvated and unsolvated forms.

[0051] The compounds of the present disclosure may have asymmetric carbon atoms. Such diastereomeric mixtures can be separated into their individual diastereomers on the basis of their different physicochemical properties by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound, separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomer mixtures and pure enantiomers are considered as part of the disclosure.

[0052] The compound of the present disclosure as an active ingredient, and the method of preparing the same, are both included in the present disclosure. Moreover, the crystalline form of some of the compounds may exist as polymorphs, and such forms may also be included in the present disclosure. Additionally, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also included within the scope of

the disclosure.

[0053] The compounds of the disclosure may be used in the free form for treatment or, when appropriate, in the form of a pharmaceutically acceptable salt or other derivative for treatment. As used herein, the term "pharmaceutically acceptable salt" refers to organic and inorganic salts of the compounds of the present disclosure which are suitable for use in human and lower animals without undue toxicity, irritation, allergic response, etc., and have reasonable benefit/risk ratio. Pharmaceutically acceptable salts of amines, carboxylic acids, phosphonates, and other types of compounds are well known in the art. The salt can be formed by reacting a compound of the disclosure with a suitable free base or acid, including, but not limited to, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid. Or the salts may be obtained by methods well known in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, lauryl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerol phosphate, glyconate, hemisulfate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, mesylate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulphate, per-3-phenylpropionate, phosphate, picrate, propionate, stearate, sulfate, thiocyanate, p-toluenesulfonate, undecanoate, and the like. Representative alkali or alkaline earth metal salts include salts of sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include suitable non-toxic salts of ammonium, quaternary ammonium, and amine cations formed from halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.

[0054] Pharmaceutical compositions of this disclosure comprise a compound of the formula (I) described herein or a pharmaceutically acceptable salt thereof; an additional agent selected from a kinase inhibitory agent (small molecule, polypeptide, antibody, etc.), an immunosuppressant, an anticancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyper proliferation compound; and any pharmaceutically acceptable carrier, adjuvant or vehicle.

[0055] The compounds of the present disclosure may be used alone or in combination with one or more of other compounds of the present disclosure or with one or more of other agents. When administered in combination, the therapeutic agents can be formulated for simultaneous or sequential administration at different times, or the therapeutic agents can be administered as a single composition. By "combination therapy", it refers to the use of a compound of the disclosure in combination with another agent in the form of co-administration of each agent or sequential administration of each agent, in either case, for the purpose of achieving the optimal results. Co-administration includes dosage form for simultaneous delivery, as well as separate dosage forms for each compound. Thus, administration of the compounds of the disclosure can be combined with other therapies known in the art, for example, radiation therapy or cytostatic agents, cytotoxic agents, other anticancer agents, and the like as used in the

treatment of cancer, in order to improve the symptoms of cancer. The administration sequence is not limited in the present disclosure. The compounds of the present disclosure may be administered before, simultaneously, or after other anticancer or cytotoxic agents.

[0056] To prepare the pharmaceutical ingredient of the present disclosure, one or more compounds of Formula (I) or salts thereof as an active ingredient can be intimately mixed with a pharmaceutical carrier, which is carried out according to a conventional pharmaceutical Formulation technique. The carrier can be used in a wide variety of forms depending on the form of preparation which is designed for different administration modes (for example, oral or parenteral administration). Suitable pharmaceutically acceptable carriers are well known in the art. A description of some of these pharmaceutically acceptable carriers can be found in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.

[0057] The pharmaceutical composition of the present disclosure may have the following forms, for example, those suitable for oral administration, such as tablets, capsules, pills, powders, sustained release forms, solutions or suspensions; those for parenteral injections such as clear solutions, suspensions, emulsion; or those for topical use such as ointments, creams; or as a suppository for rectal administration. The pharmaceutical ingredients may also be presented in unit dosage form for single administration in a precise dosage. The pharmaceutical ingredient will include a conventional pharmaceutical carrier or excipient and a compound as an active ingredient prepared according to the present disclosure, and may also include other medical or pharmaceutical preparations, carriers, adjuvants, and the like.

[0058] Therapeutic compounds can also be administered to mammals other than humans. The drug dosage for a mammal will depend on the species of the animal and its disease condition or its disordered condition. The therapeutic compound can be administered to the animal in the form of a capsule, a bolus, or a tablet or liquid. The therapeutic compound can also be introduced into the animal by injection or infusion. These drug forms are prepared in a traditional manner complying with standard veterinary practice. As an alternative, the therapeutic compounds can be mixed with the animal feed and fed to the animal, so that the concentrated feed additive or premix can be prepared by mixing ordinary animal feed.


[0059] The present disclosure also includes the use of a compound of the present disclosure, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for treating cancer (including non-solid tumors, solid tumors, primary or metastatic cancer, as indicated elsewhere herein and including one or more of other therapies to which the cancer is resistant or refractory), as well as other diseases (including, but not limited to, ocular fundus diseases, psoriasis, atheroma, pulmonary fibrosis, liver fibrosis, myelofibrosis, and the like). The cancer includes, but is not limited to any one of non-small cell lung cancer, small cell lung cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, ovarian cancer, cervical cancer, colorectal cancer, melanoma, endometrial cancer, prostate cancer, bladder cancer, leukemia, gastric cancer, liver cancer, gastrointestinal stromal tumor, thyroid cancer, chronic granulocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, nasopharyngeal

carcinoma, esophageal cancer, brain tumor, B-cell and T-cell lymphoma, lymphoma, multiple myeloma, biliary cancer and sarcoma, and cholangiocarcinoma.

[0060] In order to make the objectives, technical solutions and advantages of the present disclosure more clear, the present disclosure will be further described in detail below in conjunction with specific examples. It should be understood that the specific examples described here are only used to explain the present disclosure and are not intended to limit the present invention. If no specific technology or conditions are indicated in examples, the technology or conditions described in the literature in the art or the product specification shall be followed. If reagents or instruments used do not indicate manufacturers, they are all conventional products that are commercially available. The term "and/or" as used herein includes any and all combinations of one or more related listed items. The examples provided below can better illustrate the present disclosure. Unless otherwise specified, all temperatures are in degrees Celsius.

Intermediate: Preparation of 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

[0061]



Step 1) Preparation of 1-(8-methoxy-6-nitro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one

[0062] 1-(8-methoxy-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one (20.8 g, 100 mmol), nitric acid (22 mL) and acetic acid (44 mL) were placed in a round-bottom flask and stirred until the reaction was completed. The reaction solution was poured into crushed ice, and filtered with suction to afford 16.5 g of a yellow solid product with a yield of 66 %. ¹HNMR (400 MHz, Chloroform-d) δ 7.37 (s, 1H), 4.43 (dd, J = 5.4, 2.7 Hz, 2H), 4.35 (dd, J = 5.3, 2.7 Hz, 2H), 3.98 (s, 3H), 2.57 (s, 3H); MS: 254[M+H]⁺.

Step 2) Preparation of 1-(8-methoxy-6-amino-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one

[0063] 1-(8-methoxy-6-nitro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one (16.5 g, 65 mmol) was placed in a reaction flask, to which palladium/carbon (2 g) was then added. The mixture was stirred under hydrogen atmosphere until the reaction was completed. The reaction solution was filtered with suction and concentrated to afford 13.7 g of an off-white solid product with a yield of 95%. ¹HNMR (400 MHz, DMSO-d₆) δ 6.90 (s, 2H), 5.96 (s, 1H), 4.32 - 4.25 (m, 2H), 4.18 - 4.09 (m, 2H), 3.72 (s, 3H), 2.41 (s, 3H); MS: 224[M+H]⁺.

Step 3) Preparation of 10-hydroxy-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline


[0064] 1-(6-amino-8-methoxy-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethan-1-one (13.7 g, 62 mmol) and ethyl formate (27.5 g, 372 mmol) were dissolved in dioxane, to which sodium tert-butoxide (17.8 g, 186 mmol) was then added. The mixture was stirred until the raw materials disappeared. 10 ml of methanol was added to the reaction solution, which was then stirred until the reaction was completed. The reaction solution was neutralized with hydrochloric acid to neutrality. The mixture was then filtered with suction and concentrated to afford 14.4 g of an off-white solid product with a yield of 99%. ¹HNMR (400 MHz, DMSO-d₆) δ 11.26 (s, 1H), 7.59 (d, J = 7.3 Hz, 1H), 6.55 (s, 1H), 5.77 (d, J = 7.2 Hz, 1H), 4.34 - 4.13 (m, 4H), 3.82 (s, 3H); MS: 234[M+H]⁺.

Step 4) Preparation of 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

[0065] 10-hydroxy-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline (14.4 g, 61 mmol) was placed in a reaction flask, and dissolved by adding toluene. To the mixture were added triethylamine (42 mL, 305 mmol) and phosphorus oxychloride (17 mL, 183 mmol). The reaction solution was heated and stirred until the reaction was completed. The reaction solution was distilled to remove the solvent. The resulting solid was washed with an aqueous solution of sodium bicarbonate and then filtered with suction to afford 14.1 g of an off-white solid with a yield of 92%. ¹HNMR (400 MHz, DMSO-d₆) δ 8.51 (d, J = 4.9 Hz, 1H), 7.38 (d, J = 4.8 Hz, 1H), 7.12 (s, 1H), 4.49 - 4.29 (m, 4H), 3.93 (s, 3H); MS: 252[M+H]⁺.

Intermediate: Preparation of 1-((4-fluorophenyl)carbamoyl)cyclopropan-1-carboxylic acid


[0066]



[0067] 1,1-Cyclopropyldicarboxylic acid (1.04 g) was added to anhydrous tetrahydrofuran (20 mL). To the stirred suspension was slowly added dropwise triethylamine (0.84 g) in ice water bath, and stirred for half an hour. Thionyl chloride (1.1 g) was then added dropwise at 0 °C. After the addition, the mixture was further stirred for 1 hour. Triethylamine (0.8 g) and a solution of 4-fluoroaniline (0.9 g) in tetrahydrofuran (10 mL) were then added. After further stirring for 2 hours, the reaction was completed. The reaction solution was concentrated, dissolved in 1 N sodium hydroxide, and extracted with ethyl acetate. The aqueous phase was adjusted to pH 2.0 with a 1N solution of dilute hydrochloric acid, and further stirred for half an hour. The mixture was filtered to afford 1.1 g of a white solid product with a yield of 62%. MS: 224[M+H]⁺.

Intermediate: Preparation of 1-((4-fluorophenyl)carbamoyl)cyclopropan-1-carbonyl chloride


[0068]



[0069] A solution of 1-((4-fluorophenyl)carbamoyl)cyclopropan-1-carboxylic acid (111 mg, 0.5 mmol) in thionyl chloride (2 mL) was heated to reflux and stirred for reaction. After the reaction solution became clear, reflux was continued for 1 hour. The reaction solution was cooled and concentrated to afford 120 mg of a light yellow solid product with a yield of 100%.

Example 1. Preparation of N-(4-fluorophenyl)-N-(4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)cyclopropan-1,1-dicarboxamide

[0070]



[0071] Step 1): 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline (251 mg, 1 mmol) and p-nitrophenol (139 mg, 1 mmol) were placed in a reaction flask, to which chlorobenzene was then added. The mixture was heated to reflux and stirred until the reaction was completed. After cooling, the reaction solution was filtered with suction. The resulting solid was washed


with an aqueous solution of potassium carbonate to afford 250 mg of a pale yellow solid (5-methoxy-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline) with a yield of 71%. MS: 355[M+H]⁺.

[0072] Step 2): The product (250 mg, 0.7 mmol) obtained in step 1) was placed in a reaction flask, to which methanol and Raney nickel (250 mg) were then added. The reaction solution was stirred under hydrogen atmosphere until the reaction was completed. The reaction solution was filtered with suction and concentrated to afford 226 mg of an off-white solid product (4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline) with a yield of 99%. MS: 325[M+H]⁺.

[0073] Step 3): The product (226 mg, 0.7 mmol) obtained in step 2) and 1-((4-fluorophenyl)carbamoyl)cyclopropan-1-carboxylic acid were placed in a reaction flask, and dissolved by adding N,N-dimethylformamide. To the mixture were added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (380 mg, 1 mmol) and diethylisopropylamine (0.25 mL, 1.5 mmol), and stirred until the reaction was completed. The reaction solution was washed with an aqueous solution of sodium carbonate, filtered with suction, and subjected to column chromatography to afford 296 mg of a white solid with a yield of 80%. ¹HNMR (300 MHz, DMSO-d₆) δ 10.19 - 10.02 (m, 2H), 8.43 (d, J = 5.2 Hz, 1H), 7.78 - 7.67 (m, 2H), 7.67 - 7.56 (m, 2H), 7.22 - 7.01 (m, 5H), 6.42 (d, J = 5.3 Hz, 1H), 4.38 - 4.25 (m, 4H), 3.92 (s, 3H), 1.50 - 1.40 (m, 4H). MS: 530[M+H]⁺.

Example 2. Preparation of N-(3-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0074]



Step 1) Preparation of 10-(2-fluoro-4-nitrophenoxy)-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

[0075] Referring to step 1) of Example 1, except that an equimolar equivalent of 2-fluoro-4-nitrophenol was used in place of p-nitrophenol. ¹HNMR (400 MHz, DMSO-d₆) δ 8.67 (d, J = 5.0 Hz, 1H), 8.44 - 8.27 (m, 1H), 8.13 - 7.93 (m, 1H), 7.19 (s, 1H), 7.07 (d, J = 4.9 Hz, 1H), 6.98 (t, J = 8.7 Hz, 1H), 4.31 - 4.18 (m, 2H), 4.16 - 4.06 (m, 2H), 3.95 (s, 3H); MS: 373 [M+H]⁺.

Step 2) Preparation of 3-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline

[0076] Referring to step 2) of Example 1, except that an equimolar equivalent of 10-(2-fluoro-4-nitrophenoxy)-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline was used in place of 5-methoxy-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline. ¹HNMR (400 Hz, DMSO-d₆) δ 8.38 (d, J = 5.2 Hz, 1H), 7.05 (s, 1H), 6.99 (t, J = 9.0 Hz, 1H), 6.61 - 6.49 (m, 1H), 6.49 - 6.38 (m, 1H), 6.33 (d, J = 5.3 Hz, 1H), 5.53 - 5.37 (m, 2H), 4.36 - 4.38 (m, 4H), 3.92 (s, 3H); MS: 343[M+H]⁺.

Step 3) Preparation of N-(3-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0077] Referring to step 3) of Example 1, except that an equimolar equivalent of 3-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline was used in place of 4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline. ¹HNMR (400 MHz, DMSO-d₆) δ 10.30 (s, 1H), 9.97 (s, 1H), 8.35 (d, J = 5.2 Hz, 1H), 7.94 - 7.69 (m, 1H), 7.64 - 7.52 (m, 2H), 7.48 - 7.32 (m, 1H), 7.19 (t, J = 9.0 Hz, 1H), 7.09 (t, J = 8.8 Hz, 2H), 7.01 (s, 1H), 6.32 (d, J = 5.2 Hz, 1H), 4.28 (s, 4H), 3.85 (s, 3H), 1.55 - 1.28 (m, 4H). MS: 548[M+H]⁺.

Example 3. Preparation of N-(2-fluoro-4-((5-methoxy-2,3-dihydro-[1,4] dioxino [2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

Step 1) Preparation of 10-(3-fluoro-4-nitrophenoxy)-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

[0078] Referring to step 1) of Example 1, except that an equimolar equivalent of 3-fluoro-4-nitrophenol was used in place of p-nitrophenol. MS: 373 [M+H]⁺.


Step 2) Preparation of 2-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline

[0079] Referring to step 2) of Example 1, except that an equimolar equivalent of 10-(3-fluoro-4-nitrophenoxy)-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline was used in place of 5-methoxy-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline. ¹HNMR (400 MHz,

DMSO- d_6) δ 8.38 (d, J = 5.2 Hz, 1H), 7.04 (s, 1H), 6.98 - 6.91 (m, 1H), 6.89 - 6.79 (m, 1H), 6.78 - 6.67 (m, 1H), 6.37 (d, J = 5.2 Hz, 1H), 5.14 (s, 2H), 4.43 - 4.30 (m, 4H), 3.91 (s, 3H); MS: 343[M+H]⁺.

Step 3) Preparation of N-(2-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0080]



[0081] Referring to step 3) of Example 1, except that an equimolar equivalent of 2-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline was used in place of 4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline. ¹HNMR (400 MHz, DMSO- d_6) δ 10.49 (s, 1H), 9.97 (s, 1H), 8.50 (d, J = 5.1 Hz, 1H), 7.92 - 7.82 (m, 1H), 7.65 - 7.57 (m, 2H), 7.25 - 7.06 (m, 4H), 6.89 - 6.84 (m, 1H), 6.63 (d, J = 5.1 Hz, 1H), 4.33 - 4.22 (m, 4H), 3.92 (s, 3H), 1.63 - 1.52 (m, 4H); MS: 548[M+H]⁺.

Example 4. Preparation of N-(4-fluorophenyl)-N-(4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)cyclopropan-1,1-dicarboxamide

[0082]



[0083] Step 1) 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline (251 mg, 1 mmol) was dissolved in dichloromethane, to which 1 mol per liter of boron tribromide in dichloromethane (3 mL, 3 mmol) was then added. The mixture was stirred until the reaction

was completed. The reaction solution was concentrated to afford 236 mg of a light yellow solid product (5-hydroxy-10-chloro-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline) with a yield of 99%. MS: 238[M+H]⁺.

[0084] Step 2) The product (236 mg, 1 mmol) obtained in step 1) was dissolved in N,N-dimethylformamide, to which 4-(3-chloropropyl)morpholine (163 mg, 1 mmol) and potassium carbonate (414 mg, 3 mmol) were then added. The mixture was heated and stirred until the reaction was completed. Water was added to the reaction solution, which was then extracted with ethyl acetate. The organic phase was concentrated and then subjected to column chromatography to afford 291 mg of an off-white solid (10-chloro-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline) with a yield of 80%. ¹H NMR (400 MHz, DMSO-d₆) δ 8.50 (d, J = 4.8 Hz, 1H), 7.37 (d, J = 4.8 Hz, 1H), 7.10 (s, 1H), 4.47 - 4.30 (m, 4H), 4.17 (t, J = 6.4 Hz, 2H), 3.59 (t, J = 4.6 Hz, 4H), 2.45 (t, J = 7.1 Hz, 2H), 2.39 (d, J = 4.5 Hz, 4H), 1.97-1.95 (m, 2H). MS: 365[M+H]⁺.

Step 3) Preparation of 5-(3-morpholinopropoxy)-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

[0085] Referring to step 1) of Example 1, except that an equimolar equivalent of 10-chloro-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline was used in place of 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline. MS: 468[M+H]⁺.

Step 4) Preparation of 4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline

[0086] Referring to step 2) of Example 1, except that an equimolar equivalent of 5-(3-morpholinopropoxy)-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline was used in place of 5-methoxy-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline. ¹H NMR (400 MHz, DMSO-d₆) δ 8.33 (d, J = 5.3 Hz, 1H), 7.00 (s, 1H), 6.84 (d, J = 8.1 Hz, 2H), 6.65 (d, J = 8.2 Hz, 2H), 6.29 (d, J = 5.3 Hz, 1H), 5.10 (s, 2H), 4.35 (s, 4H), 4.20 - 4.11 (m, 2H), 3.62 - 3.56 (m, 4H), 2.48 - 2.36 (m, 6H), 2.00 - 1.91 (m, 2H). MS: 438[M+H]⁺.

Step 5) Preparation of N-(4-fluorophenyl)-N-(4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)cyclopropan-1,1-dicarboxamide

[0087] Referring to step 3) of Example 1, except that an equimolar equivalent of 4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline was used in place of 4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline. ¹H NMR (400 MHz,


DMSO-d₆) δ 10.14 (s, 1H), 10.07 (s, 1H), 8.41 (d, J = 5.3 Hz, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.63 (dd, J = 9.1, 5.1 Hz, 2H), 7.18 - 7.12 (m, 2H), 7.11 - 7.03 (m, 3H), 6.41 (d, J = 5.2 Hz, 1H), 4.37 - 4.26 (m, 4H), 4.26 - 4.10 (m, 2H), 3.68 - 3.54 (m, 4H), 2.44 - 2.39 (m, 4H), 2.02 - 1.92 (m, 2H), 1.52 - 1.41 (m, 6H); ¹³C NMR (101 MHz, DMSO-d₆) δ 168.6, 168.5, 161.3, 151.7, 151.1, 149.6, 146.7, 138.2, 136.0, 135.6, 132.28, 122.9, 122.8, 122.6, 120.7, 115.6, 115.3, 108.7, 105.7, 102.2, 67.1, 66.7, 64.4, 63.9, 55.3, 53.8, 31.9, 26.2, 15.8; MS: 643[M+H]⁺.

Example 5. Preparation of N-(3-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0088] Steps 1 and 2 are the same as Steps 1 and 2 of the preparation of Example 4.

Step 3) Preparation of 10-(2-fluoro-4-nitrophenoxy)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline


[0089]



[0090] Referring to step 3) of Example 4, except that an equimolar equivalent of 2-fluoro-4-nitrophenol was used in place of p-nitrophenol. MS: 486[M+H]⁺.

Step 4) Preparation of 3-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline

[0091]




[0092] Referring to step 2) of Example 1, except that an equimolar equivalent of 10-(2-fluoro-4-nitrophenoxy)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline was used in place of 5-methoxy-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline. ¹H NMR (400

MHz, DMSO- d_6) δ 8.37 (d, J = 5.3 Hz, 1H), 7.08 - 6.88 (m, 2H), 6.60 - 6.49 (m, 1H), 6.48 - 6.40 (m, 1H), 6.32 (d, J = 5.2 Hz, 1H), 5.44 (s, 2H), 4.37 - 4.39 (m, 4H), 4.16 (t, J = 6.4 Hz, 2H), 3.59 (t, J = 4.6 Hz, 4H), 2.46 (d, J = 7.0 Hz, 2H), 2.39 (s, 4H), 1.95 - 1.97 (m, 2H); MS: 456[M+H]⁺.

Step 5) Preparation of N-(3-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0093]




[0094] Referring to step 3) of Example 1, except that an equimolar equivalent of 3-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline was used in place of 4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline. ¹HNMR (400 MHz, DMSO- d_6) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.98 - 7.79 (m, 1H), 7.67 - 7.59 (m, 2H), 7.53 - 7.39 (m, 1H), 7.24 (t, J = 9.0 Hz, 1H), 7.18 - 7.11 (m, 2H), 7.06 (s, 1H), 6.43 - 6.34 (m, 1H), 4.37-4.34 (m, 4H), 4.17 (t, J = 6.4 Hz, 2H), 3.59 (t, J = 4.6 Hz, 4H), 2.46 (t, J = 7.1 Hz, 2H), 2.39 (d, J = 4.6 Hz, 4H), 2.08 - 1.79 (m, 2H), 1.47 (d, J = 2.3 Hz, 4H); ¹³C NMR (101 MHz, DMSO- d_6) δ 168.7, 168.4, 160.9, 151.8, 149.6, 146.6, 138.2, 133.8, 129.8, 127.7, 123.4, 122.9, 115.6, 115.4, 107.9, 102.2, 67.1, 66.7, 64.4, 63.97, 55.2, 53.8, 32.3, 26.2, 15.7; MS: 661[M+H]⁺.


Example 6. Preparation of N-(2-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0095] Steps 1 and 2 are the same as Steps 1 and 2 of the preparation of Example 4.

Step 3) Preparation of 10-(3-fluoro-4-nitrophenoxy)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

[0096]






[0097] Referring to step 3) of Example 4, except that an equimolar equivalent of 3-fluoro-4-nitrophenol was used in place of p-nitrophenol. ^1H NMR (400 MHz, DMSO- d_6) δ 8.69 (s, 1H), 8.29 - 8.09 (m, 1H), 7.51 - 7.35 (m, 1H), 7.22 - 7.08 (m, 2H), 6.97 - 6.72 (m, 1H), 4.33 - 4.16 (m, 4H), 4.12 - 3.98 (m, 2H), 3.65 - 3.54 (m, 4H), 2.47 - 2.26 (m, 6H), 2.05 - 1.82 (m, 2H). MS: 486[M+H] $^+$.

Step 4) Preparation of 2-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline


[0098]



[0099] Referring to step 2) of Example 1, except that an equimolar equivalent of 10-(3-fluoro-4-nitrophenoxy)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline was used in place of 5-methoxy-10-(4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline. ^1H NMR (400 MHz, DMSO- d_6) δ 8.37 (d, J = 5.2 Hz, 1H), 7.02 (s, 1H), 6.98 - 6.92 (m, 1H), 6.89 - 6.80 (m, 1H), 6.78 - 6.70 (m, 1H), 6.36 (d, J = 5.2 Hz, 1H), 5.13 (s, 2H), 4.35 (s, 4H), 4.15 (t, J = 6.5 Hz, 2H), 3.59 (t, J = 4.6 Hz, 4H), 2.47 (t, J = 7.2 Hz, 2H), 2.39 (d, J = 4.9 Hz, 4H), 1.95 - 1.97 (m, 2H). MS: 456[M+H] $^+$.

Step 5) Preparation of N-(2-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0100]



[0101] Referring to step 3) of Example 1, except that an equimolar equivalent of 2-fluoro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline was used in place of 4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline. ^1H NMR (400 MHz, DMSO-d_6) δ 10.48 (s, 1H), 9.97 (s, 1H), 8.50 (d, J = 5.1 Hz, 1H), 7.86 (s, 1H), 7.71 - 7.48 (m, 2H), 7.16 (dd, J = 9.9, 7.9 Hz, 2H), 7.10 (d, J = 10.5 Hz, 2H), 6.95 - 6.80 (m, 1H), 6.63 (d, J = 5.1 Hz, 1H), 4.34 - 4.28 (m, 2H), 4.27-4.24 (m, 2H), 4.17 (t, J = 6.4 Hz, 2H), 3.59 (t, J = 4.6 Hz, 4H), 2.46 (t, J = 7.2 Hz, 2H), 2.38 (d, J = 4.8 Hz, 4H), 1.95 (q, J = 6.8 Hz, 2H), 1.56-1.58 (m, 4H). MS: 661[M+H] $^+$.

Example 7. N-(4-((5-ethoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0102]



Step 1. A solution of 10-chloro-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline (2.5 g, 10 mmol), 2-fluoro-4-nitrophenol (1.6 g, 10 mmol) and potassium carbonate (2.1 g, 15 mmol) in DMF (20 mL) was heated to 80 °C for 3 hours. The reaction solution was cooled, slurried with water and filtered. The filter cake was dried to afford 3.5 g of an off-white solid product (10-(2-fluoro-4-nitrophenoxy)-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline) with a yield of 94 %;

Step 2. The product (350 mg, 1 mmol) obtained in step 1 was added to a solution of bromide hydrogen in acetic acid (33 %, 5 mL), and heated to 90 °C for 15 hours. The reaction solution was cooled, slurried with ethyl acetate (15 mL), and filtered. The filter cake was dried to afford 3.8g of a light green solid (10-(2-fluoro-4-nitrophenoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-5-ol hydrobromide) with a yield of 87%. MS: 359[M+H] $^+$;

Step 3. To a solution of the product (440 mg, 1 mmol) obtained in step 2 in DMF (5 mL) were added bromoethane (165 mg, 1.5 mmol) and potassium carbonate (280 mg, 2 mmol), respectively, and heated to 80 °C for 10 hours. After cooling, water was added to the reaction solution, which was then extracted with ethyl acetate. The extract was washed with a saturated solution of sodium chloride, dried and concentrated. The residue was purified by column chromatography to afford 320 mg of a pale yellow solid product (10-(2-fluoro-4-nitrophenoxy)-5-ethoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline) with a yield of 83%;


Step 4. To a solution of the product (320 mg) obtained in step 3 in methanol (30 mL) was

added Raney nickel, which was stirred at room temperature under hydrogen atmosphere for 3 hours. The reaction was filtered and washed. The filtrate was concentrated to afford 290 mg of a purple solid product (3-fluoro-4-((5-ethoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)aniline) with a yield of 81%. MS: 357[M+H]⁺;

Step 5. To a solution of the product (36 mg, 0.1 mmol) obtained in step 4 in NMP (1 mL) were added a solution of 1-((4-fluorophenyl)carbamoyl)cyclopropan-1-carbonyl chloride (24 mg, 0.1 mmol) in dichloromethane (0.5 mL), and triethylamine (0.1 mL), and was stirred at room temperature for 5 hours. The reaction solution was quenched with water and filtered to afford a pale yellow solid, which was purified by preparative liquid chromatography to afford 24 mg of a white solid product with a yield of 43 %. ¹H NMR (600 MHz, DMSO-d₆) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.41 (d, *J* = 5.2 Hz, 1H), 7.86 (d, *J* = 13.1 Hz, 1H), 7.63 (dd, *J* = 8.7, 5.0 Hz, 2H), 7.45 (d, *J* = 8.9 Hz, 1H), 7.25-7.13 (m, 3H), 7.05 (s, 1H), 6.39 (d, *J* = 5.2 Hz, 1H), 4.34 (s, 4H), 4.25 - 4.10 (m, 2H), 1.47 (d, *J* = 3.9 Hz, 4H), 1.41 (t, *J* = 6.9 Hz, 3H). MS: 562[M+H]⁺.

Example 8. N-(4-((5-(3-(dimethylamino)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0103]




[0104] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of dimethylaminopropyl chloride was used in place of bromoethane to afford a white solid product; ¹H NMR (400 MHz, DMSO-d₆) δ 10.32 (s, 1H), 9.99 (s, 1H), 8.41 (d, *J* = 5.2 Hz, 1H), 7.85 (dd, *J* = 13.2, 2.4 Hz, 1H), 7.68 - 7.56 (m, 2H), 7.45 (d, *J* = 8.7 Hz, 1H), 7.23 (t, *J* = 9.0 Hz, 1H), 7.15 (t, *J* = 8.9 Hz, 2H), 7.05 (s, 1H), 6.40 (d, *J* = 5.2 Hz, 1H), 4.35 (s, 4H), 4.16 (t, *J* = 6.5 Hz, 2H), 2.42-2.32 (m, 2H), 2.20 (s, 6H), 1.94 (t, *J* = 6.9 Hz, 2H), 1.47 (d, *J* = 2.3 Hz, 4H). MS: 619 [M+H]⁺.

Example 9. N-(4-((5-(3-(piperidin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0105]






[0106] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of (piperidin-1-yl)propyl chloride was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, DMSO- d_6) δ 10.31 (s, 1H), 9.99 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.85 (d, J = 13.1 Hz, 1H), 7.69 - 7.59 (m, 2H), 7.45 (d, J = 9.0 Hz, 1H), 7.23 (t, J = 9.0 Hz, 1H), 7.20 - 7.10 (m, 2H), 7.05 (s, 1H), 6.40 (d, J = 5.2 Hz, 1H), 4.35 (s, 4H), 4.16 (t, J = 6.5 Hz, 2H), 2.41 (d, J = 29.1 Hz, 6H), 1.95 (t, J = 7.4 Hz, 2H), 1.62 - 1.44 (m, 8H), 1.39 (Br, 2H). MS: 659 $[\text{M}+\text{H}]^+$.

Example 10. N-(3-fluoro-4-((5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0107]



[0108] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of methoxyethyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, DMSO- d_6) δ 10.32 (s, 1H), 9.99 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.86 (dd, J = 13.3, 2.5 Hz, 1H), 7.72 - 7.56 (m, 2H), 7.50 - 7.36 (m, 1H), 7.24 (t, J = 9.0 Hz, 1H), 7.18 - 7.11 (m, 2H), 7.08 (s, 1H), 6.40 (dd, J = 5.2, 1.0 Hz, 1H), 4.35 (s, 4H), 4.29 - 4.17 (m, 2H), 3.79 - 3.67 (m, 2H), 3.34 (s, 3H), 1.47 (d, J = 2.0 Hz, 4H). MS: 592 $[\text{M}+\text{H}]^+$.

Example 11. N-(4-((5-(cyclopropylmethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0109]



[0110] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of cyclopropylmethyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, DMSO- d_6) δ 10.31 (s, 1H), 9.99 (s, 1H), 8.40 (d, J = 5.2 Hz, 1H), 7.85 (dd, J = 13.3, 2.4 Hz, 1H), 7.63 (dd, J = 9.1, 5.1 Hz, 2H), 7.45 (d, J = 8.8 Hz, 1H), 7.26 - 7.20 (m, 1H), 7.15 (t, J = 8.9 Hz, 2H), 7.02 (s, 1H), 6.39 (d, J = 5.2 Hz, 1H), 4.35 (s, 4H), 3.97 (d, J = 7.1 Hz, 2H), 1.47 (d, J = 2.1 Hz, 4H), 1.36 - 1.25 (m, 1H), 0.73 - 0.55 (m, 2H), 0.43 - 0.31 (m, 2H). MS: 588 $[\text{M}+\text{H}]^+$.

Example 12. N-(4-((5-(isobutyloxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0111]



[0112] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of isobutyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, DMSO- d_6) δ 10.31 (s, 1H), 9.99 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.85 (dd, J = 13.3, 2.4 Hz, 1H), 7.69 - 7.57 (m, 2H), 7.50 - 7.39 (m, 1H), 7.23 (t, J = 9.0 Hz, 1H), 7.18 - 7.11 (m, 2H), 7.05 (s, 1H), 6.40 (dd, J = 5.2, 1.0 Hz, 1H), 4.35 (s, 4H), 3.90 (d, J = 6.5 Hz, 2H), 2.11 (dt, J = 13.3, 6.7 Hz, 1H), 1.47 (d, J = 2.0 Hz, 4H), 1.03 (d, J = 6.7 Hz, 6H). MS: 590 $[\text{M}+\text{H}]^+$.

Example 13. N-(3-fluoro-4-((5-(3-hydroxypropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0113]




[0114] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 3-bromopropanol was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, DMSO- d_6) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.41 (dd, J = 5.2, 0.9 Hz, 1H), 7.86 (d, J = 12.6 Hz, 1H), 7.63 (dd, J = 9.0, 4.9 Hz, 2H), 7.45 (d, J = 9.0 Hz,

1H), 7.24 (t, $J = 9.0$ Hz, 1H), 7.15 (t, $J = 8.9$ Hz, 2H), 7.06 (s, 1H), 6.39 (d, $J = 5.2$ Hz, 1H), 4.60 (t, $J = 5.1$ Hz, 1H), 4.35 (s, 4H), 4.19 (t, $J = 6.4$ Hz, 2H), 3.60 (q, $J = 5.9$ Hz, 2H), 1.95 (t, $J = 6.3$ Hz, 2H), 1.46 (q, $J = 3.3$ Hz, 4H). MS: 592 [M+H]⁺.

Example 14. N-(3-fluoro-4-((5-(3-methoxypropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0115]



[0116] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of methoxypropyl bromide was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.99 - 7.81 (m, 1H), 7.63 (dd, $J = 9.0, 5.1$ Hz, 2H), 7.45 (d, $J = 9.0$ Hz, 1H), 7.24 (t, $J = 9.0$ Hz, 1H), 7.15 (t, $J = 8.9$ Hz, 2H), 7.06 (s, 1H), 6.40 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.17 (t, $J = 6.4$ Hz, 2H), 3.51 (t, $J = 6.3$ Hz, 2H), 3.27 (s, 3H), 2.03 (t, $J = 6.4$ Hz, 2H), 1.46 (q, $J = 3.4$ Hz, 4H). MS: 606[M+H]⁺.

Example 15. N-(3-fluoro-4-((5-(3-((2-methoxyethyl)(methyl)amino)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0117]




[0118] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 3-bromo-N-(2-methoxyethyl)-N-methylpropan-1-amine was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.33 (s, 1H), 10.01 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.86 (dd, $J = 13.2, 2.4$ Hz, 1H), 7.68 - 7.59 (m, 2H), 7.45 (dt, $J = 8.8, 1.6$ Hz, 1H), 7.24 (t, $J = 9.0$ Hz, 1H), 7.20 - 7.09 (m, 2H), 7.05 (s, 1H), 6.39 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.15 (t, $J = 6.4$ Hz, 2H), 3.41 (t, $J = 5.9$ Hz, 2H), 3.21 (s, 3H), 2.52 (td, $J = 6.6, 6.1, 4.4$ Hz, 4H), 2.22 (s, 3H), 1.93 (q, $J = 6.7$ Hz, 2H), 1.47 (q, $J = 3.3$,

2.9 Hz, 4H). MS: 663 [M+H]⁺.

Example 16. N-(3-fluoro-4-((5-isopropoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0119]



[0120] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of isopropyl bromide was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-d₆) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.40 (d, *J* = 5.2 Hz, 1H), 7.86 (dd, *J* = 13.2, 2.5 Hz, 1H), 7.65 - 7.62 (m, 2H), 7.45 (dd, *J* = 8.9, 1.9 Hz, 1H), 7.22 (d, *J* = 9.1 Hz, 1H), 7.17 - 7.13 (m, 2H), 7.06 (s, 1H), 6.38 (d, *J* = 5.2 Hz, 1H), 4.82 - 4.80 (m, 1H), 4.34 (s, 4H), 1.47 (t, *J* = 3.5 Hz, 4H), 1.36 (d, *J* = 6.0 Hz, 6H). MS: 576[M+H]⁺.

Example 17. N-(3-fluoro-4-((5-((tetrahydrofuran-3-yl)oxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0121]



[0122] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of tetrahydrofuran-3-yl p-toluenesulfonate was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-d₆) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.42 (d, *J* = 5.2 Hz, 1H), 7.86 (dd, *J* = 13.2, 2.4 Hz, 1H), 7.67 - 7.57 (m, 2H), 7.45 (dd, *J* = 8.4, 2.1 Hz, 1H), 7.24 (t, *J* = 9.0 Hz, 1H), 7.15 (t, *J* = 8.9 Hz, 2H), 7.03 (s, 1H), 6.40 (d, *J* = 5.2 Hz, 1H), 5.24 - 5.16 (m, 1H), 4.35 (s, 4H), 3.96 (dd, *J* = 10.3, 4.5 Hz, 1H), 3.92 - 3.84 (m, 2H), 3.78 (td, *J* = 8.3, 4.7 Hz, 1H), 2.36 - 2.29 (m, 1H), 2.09 - 2.03 (m, 1H), 1.47 (q, *J* = 3.3 Hz, 4H). MS: 604[M+H]⁺.

Example 18. N-(3-fluoro-4-((5-((tetrahydropyran-4-yl)oxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0123]



[0124] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of tetrahydropyran-4-yl p-toluenesulfonate was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.90 - 7.81 (m, 1H), 7.63 (dd, $J = 9.0, 5.1$ Hz, 2H), 7.46 (d, $J = 8.8$ Hz, 1H), 7.24 (t, $J = 9.1$ Hz, 1H), 7.18 - 7.14 (m, 3H), 6.39 (d, $J = 5.2$ Hz, 1H), 4.80 (dt, $J = 9.0, 4.7$ Hz, 1H), 4.35 (s, 4H), 3.89 (dt, $J = 11.6, 4.3$ Hz, 2H), 3.55 (ddd, $J = 12.0, 9.8, 2.7$ Hz, 2H), 2.07 (d, $J = 10.7$ Hz, 2H), 1.67 (dtd, $J = 13.2, 9.3, 4.1$ Hz, 2H), 1.50 - 1.39 (m, 4H). MS: 618 $[\text{M}+\text{H}]^+$.

Example 19. N-(4-((5-(3-(4-(acetylpiperazin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0125]



[0126] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 4-acetylpiperazin-1-ylpropyl chloride was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.26 (s, 1H), 9.93 (s, 1H), 8.35 (d, $J = 5.2$ Hz, 1H), 7.79 (dd, $J = 13.3, 2.4$ Hz, 1H), 7.64 - 7.49 (m, 2H), 7.42 - 7.33 (m, 1H), 7.17 (t, $J = 9.1$ Hz, 1H), 7.12 - 7.05 (m, 2H), 7.01 (s, 1H), 6.36 - 6.25 (m, 1H), 4.29 (s, 4H), 4.12 (t, $J = 6.4$ Hz, 2H), 3.38 (s, 4H), 2.48 (br, 2H), 2.41 - 2.11 (m, 4H), 1.93 (s, 5H), 1.40 (q, $J = 3.2$ Hz, 4H). MS: 702 $[\text{M}+\text{H}]^+$.

Example 20. N-(4-((5-(cyanomethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0127]



[0128] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of bromoacetonitrile was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.34 (s, 1H), 10.00 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 7.87 (dd, J = 13.3, 2.4 Hz, 1H), 7.68 - 7.59 (m, 2H), 7.50 - 7.43 (m, 1H), 7.33 - 7.23 (m, 2H), 7.20 - 7.10 (m, 2H), 6.49 - 6.43 (m, 1H), 5.38 (s, 2H), 4.38 (s, 4H), 1.47 (q, J = 3.4 Hz, 4H). MS: 573 $[\text{M}+\text{H}]^+$.

Example 21. N-(4-((5-(3-(4-methylpiperazin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0129]




[0130] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 4-methylpiperazin-1-ylpropyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.41 (dd, J = 5.2, 1.4 Hz, 1H), 7.86 (d, J = 13.2 Hz, 1H), 7.63 (dd, J = 8.7, 5.1 Hz, 2H), 7.45 (d, J = 8.9 Hz, 1H), 7.24 (t, J = 9.2 Hz, 1H), 7.15 (td, J = 8.8, 1.5 Hz, 2H), 7.05 (d, J = 1.4 Hz, 1H), 6.39 (d, J = 5.3 Hz, 1H), 4.35 (s, 4H), 4.18 - 4.13 (m, 2H), 2.45 (t, J = 7.2 Hz, 2H), 2.40 - 2.29 (m, 8H), 2.14 (s, 3H), 1.94 (t, J = 6.9 Hz, 2H), 1.47 (d, J = 3.8 Hz, 4H). MS: 674 $[\text{M}+\text{H}]^+$.

Example 22. N-(3-fluoro-4-((5-(3-(4-hydroxy-4-methylpiperidin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0131]






[0132] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of (4-hydroxy-4-methylpiperidin-1-yl)propyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.86 (dd, $J = 13.1, 2.4$ Hz, 1H), 7.66 - 7.60 (m, 2H), 7.45 (dt, $J = 8.5, 1.7$ Hz, 1H), 7.24 (t, $J = 9.0$ Hz, 1H), 7.17 - 7.11 (m, 2H), 7.05 (s, 1H), 6.39 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.16 (t, $J = 6.4$ Hz, 2H), 2.50 (br, 4H), 2.42 (br, 2H), 2.01 - 1.90 (m, 2H), 1.55 - 1.42 (m, 8H), 1.10 (s, 3H). MS: 689[M+H] $^+$.

Example 23. N-(4-((5-(3-(cyclobutyl(methyl)amino)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0133]




[0134] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 3-(cyclobutyl(methyl)amino)propyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 10.01 (s, 1H), 8.42 (d, $J = 5.2$ Hz, 1H), 7.87 (dd, $J = 13.2, 2.5$ Hz, 1H), 7.67 - 7.59 (m, 2H), 7.46 (dt, $J = 8.9, 1.7$ Hz, 1H), 7.25 (t, $J = 9.0$ Hz, 1H), 7.19 - 7.11 (m, 2H), 7.06 (s, 1H), 6.40 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.16 (t, $J = 6.4$ Hz, 2H), 2.79 (t, $J = 7.6$ Hz, 1H), 2.38 (t, $J = 7.0$ Hz, 2H), 2.06 (s, 3H), 2.02 - 1.94 (m, 2H), 1.91 (p, $J = 6.7$ Hz, 2H), 1.76 (ddd, $J = 11.2, 6.4, 2.2$ Hz, 2H), 1.65 - 1.55 (m, 2H), 1.47 (dd, $J = 4.4, 3.0$ Hz, 4H). MS: 659[M+H] $^+$.

Example 24. N-(4-((5-(3-(1,1-dioxothiomorpholin-4-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0135]






[0136] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 3-(1,1-dioxothiomorpholin-4-yl)propyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.86 (dd, $J = 13.2, 2.4$ Hz, 1H), 7.63 (dd, $J = 8.9, 5.2$ Hz, 2H), 7.45 (dd, $J = 8.9, 2.3$ Hz, 1H), 7.24 (t, $J = 9.0$ Hz, 1H), 7.15 (t, $J = 8.9$ Hz, 2H), 7.09 (s, 1H), 6.39 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.18 (t, $J = 6.4$ Hz, 2H), 3.11 (t, $J = 5.2$ Hz, 4H), 2.92 (dd, $J = 7.2, 3.5$ Hz, 4H), 2.65 (t, $J = 7.0$ Hz, 2H), 1.96 (p, $J = 6.7$ Hz, 2H), 1.47 (q, $J = 3.3$ Hz, 4H). MS:709[M+H] $^+$.

Example 25. N-(3-fluoro-4-((5-(3-(pyrrolidin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0137]



[0138] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 3-(pyrrolidin-1-yl)propyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.34 (s, 1H), 10.01 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.86 (dd, $J = 13.1, 2.4$ Hz, 1H), 7.63 (dd, $J = 8.9, 5.0$ Hz, 2H), 7.45 (dd, $J = 8.9, 2.3$ Hz, 1H), 7.24 (t, $J = 9.0$ Hz, 1H), 7.15 (t, $J = 8.8$ Hz, 2H), 7.06 (s, 1H), 6.40 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.18 (t, $J = 6.4$ Hz, 2H), 2.73 (t, $J = 7.3$ Hz, 2H), 2.66 (d, $J = 5.9$ Hz, 4H), 2.03 (q, $J = 6.9$ Hz, 2H), 1.80 - 1.68 (m, 4H), 1.47 (t, $J = 3.9$ Hz, 4H). MS:645[M+H] $^+$.

Example 26. N-(3-fluoro-4-((5-(3-cyanopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0139]



[0140] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of bromobutyronitrile was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.42 (d, J = 5.2 Hz, 1H), 7.86 (dd, J = 13.2, 2.4 Hz, 1H), 7.63 (dd, J = 9.0, 5.1 Hz, 2H), 7.45 (dd, J = 9.0, 2.3 Hz, 1H), 7.24 (t, J = 9.0 Hz, 1H), 7.15 (t, J = 8.9 Hz, 2H), 7.10 (s, 1H), 6.41 (d, J = 5.2 Hz, 1H), 4.36 (s, 4H), 4.20 (t, J = 6.1 Hz, 2H), 2.69 (t, J = 7.2 Hz, 2H), 2.12 (p, J = 6.7 Hz, 2H), 1.47 (t, J = 3.6 Hz, 4H). MS:601[M+H] $^+$.

Example 27. N-(4-((5-((6-(dimethylamino)hexyl)oxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0141]



[0142] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 6-dimethylaminohexyl bromide was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.34 (s, 1H), 10.01 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.86 (d, J = 13.0 Hz, 1H), 7.63 (dd, J = 8.8, 5.1 Hz, 2H), 7.45 (d, J = 8.9 Hz, 1H), 7.24 (t, J = 9.0 Hz, 1H), 7.15 (t, J = 8.7 Hz, 2H), 7.05 (s, 1H), 6.39 (d, J = 5.2 Hz, 1H), 4.35 (s, 4H), 4.12 (t, J = 6.5 Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H), 2.20 (s, 6H), 1.80 (q, J = 7.1 Hz, 2H), 1.49-1.43 (m, 8H), 1.36 (q, J = 7.8 Hz, 2H). MS:661[M+H] $^+$.

Example 28. N-(3-fluoro-4-((5-(oxetan-3-yloxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0143]




[0144] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of oxetan-3-yl p-toluenesulfonate was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 10.00 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.87 (d, J = 13.2 Hz, 1H), 7.73 - 7.57 (m, 2H), 7.45 (s, 1H), 7.24 (s,

1H), 7.15 (t, $J = 8.8$ Hz, 2H), 6.70 (s, 1H), 6.41 (d, $J = 5.2$ Hz, 1H), 5.45 (h, $J = 5.1$ Hz, 1H), 5.07 - 4.87 (m, 2H), 4.62 (dd, $J = 7.4, 4.9$ Hz, 2H), 4.38 (s, 4H), 1.45 (s, 4H). MS:590[M+H]⁺.

Example 29. N-(3-fluoro-4-((5-(3-(4,4-dimethylpiperidin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0145]



[0146] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of (4,4-dimethylpiperidin-1-yl)propyl bromide was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.41 (d, $J = 5.2$ Hz, 1H), 7.89 - 7.81 (m, 1H), 7.63 (dd, $J = 9.0, 5.1$ Hz, 2H), 7.45 (d, $J = 8.7$ Hz, 1H), 7.24 (t, $J = 9.1$ Hz, 1H), 7.15 (t, $J = 8.9$ Hz, 2H), 7.05 (s, 1H), 6.39 (d, $J = 5.2$ Hz, 1H), 4.35 (s, 4H), 4.15 (t, $J = 6.4$ Hz, 2H), 2.46 - 2.36 (m, 6H), 1.98 - 1.92 (m, 2H), 1.47 (q, $J = 3.3$ Hz, 4H), 1.35 - 1.30 (m, 4H), 0.90 (s, 6H). MS:687[M+H]⁺.

Example 30. N-(3-fluoro-4-((5-(3-(4-amino-4-methylpiperidin-1-yl)propoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0147]




[0148] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of (4-amino-4-methylpiperidin-1-yl)propyl bromide was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.31 (s, 1H), 9.97 (s, 1H), 8.34 (d, $J = 5.2$ Hz, 1H), 8.30 (s, 2H), 7.79 (dd, $J = 13.2, 2.4$ Hz, 1H), 7.61 - 7.50 (m, 2H), 7.39 (dt, $J = 8.7, 1.7$ Hz, 1H), 7.17 (t, $J = 9.1$ Hz, 1H), 7.12 - 7.04 (m, 2H), 6.98 (s, 1H), 6.33 (d, $J = 5.2$ Hz, 1H), 4.28 (s, 4H), 4.09 (t, $J = 6.4$ Hz, 2H), 2.59 - 2.52 (m, 4H), 2.19 (s,

2H), 1.92 - 1.84 (m, 2H), 1.66 - 1.48 (m, 4H), 1.40 (dd, $J = 5.4, 3.6$ Hz, 4H), 1.14 (s, 3H). MS: 688[M+H]⁺.

Example 31. N-(3-chloro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0149]



[0150] The preparation was carried out in a similar manner to Example 7, except that in step 1, 2-chloro-4-nitrophenol was used in place of 2-fluoro-4-nitrophenol, and in step 3, 4-(3-chloropropyl)morpholine was used in place of bromoethane to afford a white solid product; ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.28 (s, 1H), 10.02 (s, 1H), 8.43 (d, $J = 5.2$ Hz, 1H), 8.05 (d, $J = 2.5$ Hz, 1H), 7.69 - 7.62 (m, 2H), 7.60 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.22 - 7.13 (m, 3H), 7.09 (s, 1H), 6.34 (d, $J = 5.2$ Hz, 1H), 4.38 - 4.30 (m, 4H), 4.20 (t, $J = 6.3$ Hz, 2H), 3.63 (s, 4H), 2.42 (br, 6H), 2.01 (d, $J = 16.4$ Hz, 2H), 1.47 (t, $J = 3.1$ Hz, 4H). MS: 677[M+H]⁺.


Example 32. N-(3-fluoro-4-((5-(2-hydroxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0151]




[0152] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 2-bromoethanol was used in place of bromoethane to afford a white solid product; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 10.01 (s, 1H), 8.44 (d, $J = 5.3$ Hz, 1H), 7.87 (dd, $J = 13.2, 2.4$ Hz, 1H), 7.64 (dd, $J = 8.9, 5.1$ Hz, 2H), 7.47 (dd, $J = 8.9, 2.3$ Hz, 1H), 7.26 (t, $J = 9.0$ Hz, 1H), 7.15 (t, $J = 8.9$ Hz, 2H), 7.09 (s, 1H), 6.43 (d, $J = 5.3$ Hz, 1H), 4.96 (s, 1H), 4.36 (s, 4H), 4.15 (t, $J = 4.9$ Hz, 2H), 3.81 (t, $J = 4.9$ Hz, 2H), 1.48 (t, $J = 2.9$ Hz, 4H). MS: 578[M+H]⁺.

Example 33. N-(4-((5-((1-aminocyclopropyl)methoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

f]quinolin-10-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide**[0153]**


[0154] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of (1-((tertbutyloxycarbonyl)amino)cyclopropyl)methyl 4-methylbenzenesulfonate was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.40 (d, J = 5.2 Hz, 1H), 7.85 (dd, J = 13.3, 2.4 Hz, 1H), 7.73 - 7.57 (m, 2H), 7.45 (dd, J = 8.9, 2.3 Hz, 1H), 7.19 (dt, J = 35.1, 9.0 Hz, 3H), 7.03 (s, 1H), 6.39 (d, J = 5.1 Hz, 1H), 4.36 (q, J = 4.5 Hz, 4H), 4.02 (s, 2H), 1.47 (t, J = 2.9 Hz, 4H), 0.62 (dt, J = 9.6, 2.1 Hz, 4H). MS: 603[M+H] $^+$.

Example 34. N-(3-fluoro-4-((5-(2-hydroxy-2-methylpropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide**[0155]**

[0156] The preparation was carried out in a similar manner to Example 7, except that in step 3, an equimolar equivalent of 1-bromo-2-methylpropan-2-ol was used in place of bromoethane to afford a white solid product; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.32 (s, 1H), 10.00 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 7.86 (dd, J = 13.2, 2.4 Hz, 1H), 7.69 - 7.59 (m, 2H), 7.49 - 7.40 (m, 1H), 7.24 (t, J = 9.0 Hz, 1H), 7.19 - 7.11 (m, 2H), 7.04 (s, 1H), 6.40 (dd, J = 5.2, 1.0 Hz, 1H), 4.69 (s, 1H), 4.36 (d, J = 1.8 Hz, 4H), 3.87 (s, 2H), 1.47 (t, J = 2.7 Hz, 4H), 1.25 (s, 6H). MS: 606[M+H] $^+$.

Example 35. N-(2-chloro-5-fluoro-4-((5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide


[0157]



[0158] The preparation was carried out in a similar manner to Example 7, except that in step 1, an equimolar equivalent of 5-chloro-2-fluoro-4-nitrophenol was used in place of 2-fluoro-4-nitrophenol to afford a white solid product; ^1H NMR (400 MHz, DMSO- d_6) δ 11.37 (s, 1H), 9.72 (s, 1H), 8.46 (d, J = 5.1 Hz, 1H), 8.26 (d, J = 12.8 Hz, 1H), 7.63 - 7.48 (m, 3H), 7.18 (t, J = 8.9 Hz, 2H), 7.09 (s, 1H), 6.57 (d, J = 5.2 Hz, 1H), 4.32 (s, 4H), 3.92 (s, 3H), 1.71 (s, 2H), 1.63 (s, 2H). MS: 582[M+H] $^+$.

Example 36. N-(2-chloro-4-((5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-fluquinolin-10-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropan-1,1-dicarboxamide

[0159]



[0160] The preparation was carried out in a similar manner to Example 7, except that in step 1, an equimolar equivalent of 3-chloro-4-nitrophenol was used in place of 2-fluoro-4-nitrophenol, and in step 3, an equimolar equivalent of 4-(3-chloropropyl)morpholine was used in place of bromoethane to afford a white solid product; ^1H NMR (600 MHz, DMSO- d_6) δ 10.83 (s, 1H), 9.89 (s, 1H), 8.51 (d, J = 5.1 Hz, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.59 (dd, J = 8.9, 5.1 Hz, 2H), 7.28 (d, J = 2.7 Hz, 1H), 7.18 (t, J = 8.9 Hz, 2H), 7.13 (d, J = 9.2 Hz, 1H), 7.05 (dd, J = 9.0, 2.8 Hz, 1H), 6.64 (d, J = 5.1 Hz, 1H), 4.36 - 4.14 (m, 6H), 3.84 - 3.63 (m, 2H), 3.26 (s, 4H), 2.51 (br, 4H), 2.26 - 2.11 (m, 2H), 1.66 (q, J = 4.3, 3.7 Hz, 2H), 1.60 (q, J = 4.9, 4.2 Hz, 2H). MS: 677[M+H] $^+$.

Biological Example 1. Assay of small molecular compounds for inhibiting the activity of c-MET kinase

[0161] The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:

1. 1. Dilution of compounds: a total of 11 concentrations were obtained using a 3-fold gradient dilution from the highest concentration of 2500 nM (the maximum final concentration of the drug used in this assay was 2500 nM, and the minimum final concentration was 0.042 nM).
2. 2. 2.5 μ L of the gradient-diluted compounds were taken with a transfer pipette to a 384-well plate.
3. 3. Addition of enzyme: 5 μ L of 2X c-MET kinase solution (concentration was 2 nM) was taken with a transfer pipette to the corresponding reaction well of the 384-well plate, mixed well and pre-reacted at room temperature for 5 minutes.
4. 4. 2.5 μ L 4X Ultra ULight™-JAK-1 (Tyr1023) Peptide (concentration was 400 nM)/ATP (concentration was 40 μ M) mixture was taken with a transfer pipette to the corresponding reaction well of the 384-well plate.
5. 5. Negative control: 2.5 μ L/well 4X substrate/ATP mixture and 7.5 μ L 1X Kinase Assay Buffer were added to the wells of the 384-well plate.
6. 6. Positive control: 2.5 μ L/well 4X substrate/ATP mixture, 2.5 μ L/well 1X Kinase Assay Buffer containing 16 % DMSO, and 5 μ L/well 2X c-MET kinase solution were added to the 384-well plate. The final concentration of DMSO in the reaction system was 4 %.
7. 7. The mixture was mixed well and then centrifuged and reacted at room temperature in dark for 60 min.
8. 8. Termination of the enzymatic reaction: 5 μ L of 4X stop solution was taken with a transfer pipette to the wells of the 384-well plate, mixed and then centrifuged, and reacted at room temperature for 5 min.
9. 9. Development of the reaction: 5 μ L of 4X detection solution was taken with a transfer pipette to the wells of the 384-well plate for color development, and the mixture was mixed and then centrifuged and reacted at room temperature for 60 min.
10. 10. The 384-well plate was placed into the Envision plate reader and the signal was detected using the appropriate program.
11. 11. Analysis and processing of the raw data:
12. 12. The drug concentrations and the corresponding inhibition rates were input into GraphPad Prism5 for calculation, and the inhibition rate of the compounds were calculated as follows: inhibition rate (%) = (reading of positive well - reading of experimental well) / (reading of positive control well - reading of negative control well) $\times$ 100%. Processing with GraphPad Prism5 software yielded the corresponding IC₅₀ values (the concentration of the compound at which 50% of the highest inhibition of the enzyme is achieved).

[0162] Table 1 lists the assay results of the inhibitory activity of some of the compounds disclosed herein on the c-MET tyrosine kinase, wherein A indicates that the IC₅₀ is less than or equal to 50 nM, B indicates that the IC₅₀ is greater than 50 nM but less than or equal to 500 nM, C indicates that the IC₅₀ is greater than 500 nM but less than or equal to 5000 nM, and D indicates that the IC₅₀ is greater than 5000 nM.

Table 1. Assay results of the inhibitory activity of the compounds disclosed herein on the c-MET tyrosine kinase

Example No.	c-MET IC ₅₀ (nM)	Example No.	c-MET IC ₅₀ (nM)
1	A	19	A
2	A	20	A
3	A	21	A
4	A	22	A
5	A	23	A
6	A	24	A
7	A	25	A
8	A	26	A
9	A	27	A
10	A	28	A
11	B	29	A
12	B	30	A
13	A	31	A
14	A	32	A
15	A	33	A
16	A	34	A
17	A	35	A
18	A	36	A

Biological Example 2. Assay of small molecular compounds for inhibiting the activity of VEGFR-2 kinase

[0163] The assay is based on the LANCE TR-FRET technology of Perkin Elmer Inc., and the assay method is as follows:

1. Dilution of compounds: a total of 11 concentrations were obtained using a 3-fold gradient dilution from the highest concentration of 2500 nM (the maximum final concentration of the drug used in this assay was 2500 nM, and the minimum final concentration was 0.042 nM).
2. 2.5 μ L of the gradient-diluted compounds were taken with a transfer pipette to a 384-well plate.
3. Addition of enzyme: 5 μ L of 2X VEGFR-2 kinase solution (concentration was 0.5 nM) was taken with a transfer pipette to the corresponding reaction well of the 384-well plate, mixed well and pre-reacted at room temperature for 30 minutes.

4. 4. 2.5µL 4X Ultra ULight™-JAK-1 (Tyr1023) Peptide (concentration was 200 nM)/ATP (concentration was 40 µM) mixture was taken with a transfer pipette to the corresponding reaction well of the 384-well plate.
5. 5. Negative control: 2.5 µL/well 4X substrate/ATP mixture and 7.5 µL 1X Kinase Assay Buffer were added to the wells of the 384-well plate.
6. 6. Positive control: 2.5 µL/well 4X substrate/ATP mixture, 2.5 µL/well 1X Kinase Assay Buffer containing 16 % DMSO, and 5 µL/well 2X VEGFR-2 kinase solution were added to the 384-well plate. The final concentration of DMSO in the reaction system was 4 %.
7. 7. The mixture was mixed well and then centrifuged and reacted at room temperature in dark for 60 min.
8. 8. Termination of the enzymatic reaction: 5 µL of 4X stop solution was taken with a transfer pipette to the wells of the 384-well plate, mixed and then centrifuged, and reacted at room temperature for 5 min.
9. 9. Development of the reaction: 5 µL of 4X detection solution was taken with a transfer pipette to the wells of the 384-well plate for color development, and the mixture was mixed and then centrifuged and reacted at room temperature for 60 min.
10. 10. The 384-well plate was placed into the Envision plate reader and the signal was detected using the appropriate program.
11. 11. Analysis and processing of the raw data:

The drug concentrations and the corresponding inhibition rates were input into GraphPad Prism5 for calculation, and the inhibition rate of the compounds were calculated as follows: inhibition rate (%) = (reading of positive well - reading of experimental well) / (reading of positive control well - reading of negative control well) × 100%. Processing with GraphPad Prism5 software yielded the corresponding IC₅₀ values (the concentration of the compound at which 50% of the highest inhibition of the enzyme is achieved).

[0164] Table 2 lists the assay results of the inhibitory activity of some of the compounds disclosed herein on the VEGFR-2 tyrosine kinase, wherein A indicates that the IC₅₀ is less than or equal to 50 nM, B indicates that the IC₅₀ is greater than 50 nM but less than or equal to 500 nM, C indicates that the IC₅₀ is greater than 500 nM but less than or equal to 5000 nM, and D indicates that the IC₅₀ is greater than 5000 nM.

Table 2. Assay results of the inhibitory activity of some of the compounds disclosed herein on the VEGFR-2 tyrosine kinase

Example No.	VEGFR-2 IC ₅₀ (nM)	Example No.	VEGFR-2 IC ₅₀ (nM)
1	A	20	B
2	A	21	A
3	A	22	A
4	A	23	A

Example No.	VEGFR-2 IC ₅₀ (nM)	Example No.	VEGFR-2 IC ₅₀ (nM)
5	A	24	A
6	A	25	A
7	A	26	A
8	A	27	A
9	A	28	A
10	A	29	A
13	A	30	A
14	A	32	A
15	A	33	A
17	A	34	A
18	B	35	D
19	A	36	B

Biological Example 3. Assay of the inhibitory activity of small molecular compounds on the proliferation of MHCC97H cells

[0165] The specific steps of the assay are as follows:

1. 1. Dilution of compounds: a total of 9 concentrations were obtained using a 3-fold gradient dilution from the highest concentration of 5000 nM (the maximum final concentration of the drug used in this assay was 5000 nM, and the minimum final concentration was 0.76 nM).
2. 2. MHCC97H cells were collected, then transferred to a 15 mL centrifuge tube, and centrifuged at 1000 rpm for 5 minutes.
3. 3. The supernatant was discarded, and the complete medium was added and pipetted evenly, 10 μ L of cell suspension was taken out and mixed evenly with 10 μ L of 0.4% trypan blue, the counting was carried out with a cell counter, and the number and survival rate of cells were recorded;
4. 4. The cell suspension was seeded into a 96-well plate at 5000 cells/80 μ L per well;
5. 5. 20 μ L of the corresponding 5 $\times$ compound solution diluted with the medium mentioned above was added to each well and mixed evenly;
6. 6. After 72 hours of incubation, 10 μ L of CCK-8 reagent was added to each well and incubated for another 2 hours (the reaction time can be adjusted according to the color depth);
7. 7. The OD value was read at 450 nm on a multi-function plate reader.
8. 8. Data processing: cell survival rate (%) = [(As-Ab)/(Ac-Ab)] * 100%

As: OD value of assay well (medium containing cells, CCK-8, compound),

Ac: OD value of control well (medium containing cells, CCK-8),

Ab: OD value of blank well (CCK-8, medium without cell and compound),

The values were then imported into Graphpad Prism5 software for curve fitting, and IC_{50} was calculated.

[0166] Table 3 lists the assay results of the inhibitory activity of some compounds disclosed herein on the proliferation of the MHCC97H cell line.

Table 3. The assay results of the inhibitory activity of some compounds disclosed herein on the proliferation of MHCC97H cells

Example No.	MHCC97H IC_{50} (nM)	Example No.	MHCC97H IC_{50} (nM)
1	< 50	20	< 50
2	< 50	21	< 50
3	< 50	22	< 50
4	< 50	23	< 50
5	< 50	24	< 50
6	< 50	25	< 50
7	< 50	26	< 50
8	< 50	27	< 50
9	< 50	28	< 50
10	< 50	29	< 50
13	< 50	30	< 500
14	< 50	32	< 50
15	< 50	33	< 50
17	< 50	35	< 50
19	< 50	36	< 50

[0167] The biological data provided by the present disclosure indicate that the compounds disclosed herein are useful for treating or preventing diseases caused by abnormalities of VEGFR-2 or c-MET kinase. Therefore, the compounds disclosed herein are useful in the treatment of cancer, including primary and metastatic cancers, including solid tumors. Such cancers include, but are not limited to, non-small cell lung cancer, small cell lung cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, ovarian cancer, cervical cancer, colorectal cancer, melanoma, endometrial cancer, prostate cancer, bladder cancer, leukemia, gastric

cancer, liver cancer, gastrointestinal stromal tumor, thyroid cancer, chronic granulocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, nasopharyngeal carcinoma, esophageal cancer, brain tumor, B-cell and T-cell lymphoma, lymphoma, multiple myeloma, biliary cancer and sarcoma, cholangiocarcinoma, etc. The compounds disclosed herein also treat cancers that are resistant to one or more other therapeutic methods. The compounds disclosed herein can also be used for other diseases (besides cancer) related to VEGFR-2 kinase and/or c-MET kinase, including but not limited to ocular fundus diseases, psoriasis, rheumatic arthritis, atherosclerosis, pulmonary fibrosis, and liver fibrosis. The compounds disclosed herein can be used as monotherapy or combination therapy, and can be used in combination with multiple compounds disclosed herein or in combination with other drugs than the present disclosure.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- EP3246328A [0007]

Non-patent literature cited in the description

- **JAKEMAN et al.**Endocrinology, 1993, vol. 133, 848-859 [0003]
- **KOLCH et al.**Breast Cancer Research and Treatment, 1995, vol. 36, 139-155 [0003]
- **CONNOLLY et al.**J. Biol. Chem., 1989, vol. 264, 20017-20024 [0003]
- **KIM et al.**Nature, 1993, vol. 362, 841-844 [0003]
- Handbook of Pharmaceutical Excipients American Pharmaceutical Association and the Pharmaceutical Society of Great Britain [0056]

Patentkrav

1. Forbindelse med formel (I), eller et farmaceutisk acceptabelt salt, en enantiomer eller en diastereomer, et hydrat eller et solvat deraf,




5 i formlen (I),

Q er CH;

G er O;

Z er CH;

L er valgt fra gruppen bestående af



10

hvor X er H eller C₁-C₃-alkyl; Y er H eller C₁-C₃-alkyl; n er 0 til 3, og når n er 0, repræsenterer L



15

R¹ er H, C₁-C₉-alkyl, C₃-C₇-cycloalkyl, 4- til 7-leddet heterocyclyl, C₁-C₆-alkyl substitueret med C₃-C₇-cycloalkyl, C₁-C₆-alkyl substitueret med 4- til 7-leddet heterocyclyl, eller C₁-C₉-alkyl substitueret med en eller flere af de følgende: hydroxyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio eller -NR⁶R⁷,

R⁶ og R⁷ er hver uafhængigt H, C₁-C₆-alkyl, C₁-C₆-alkyl substitueret med hydroxyl, eller C₁-C₆-alkyl substitueret med C₁-C₃-alkoxy;

20


den ovennævnte 4- til 7-leddet heterocyclyl er en 4- til 7-leddet heterocyclyl indeholdende 1 til 2 atomer valgt fra gruppen bestående af N, O og S, som er ikke-substitueret, eller er substitueret med C₁-C₃-alkyl eller C₁-C₃-acyl, eller er oxideret med 1 til 2 oxygenatomer;
R² er H, C₁-C₃-alkyl eller halogen;

- R^3 er H, C_1 - C_3 -alkyl eller halogen;
 R^4 er H, C_1 - C_3 -alkyl eller halogen;
 R^5 er H, C_1 - C_9 -alkyl, C_3 - C_7 -cycloalkyl, C_1 - C_6 -alkyl substitueret med C_3 - C_7 -cycloalkyl, aryl, C_1 - C_6 -alkyl substitueret med aryl, heteroaryl, eller C_1 - C_6 -alkyl substitueret med heteroaryl;
 5 arylen og heteroarylen er ikke-substitueret, eller substitueret med en eller flere af de følgende: C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy, C_1 - C_3 -alkylthio, amino substitueret med mono- eller di- C_1 - C_3 -alkyl, halogen, trifluormethyl, aryloxy og methylsulfonyl; og
 10 den ovennævnte heteroaryl er en monocyklisk eller bicyklisk gruppe indeholdende 1 til 3 heteroatomer valgt fra gruppen bestående af N, O og S, og indeholdende 5 til 10 ringatomer.
2. Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge krav 1, hvor R^1 er H, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, 5- til 6-leddet heterocyclyl, C_1 - C_3 -alkyl substitueret med C_3 - C_6 -cycloalkyl, C_1 - C_3 -alkyl substitueret med 5- til 6-leddet heterocyclyl, eller C_1 - C_6 -alkyl substitueret med de følgende: hydroxyl, C_1 - C_3 -alkoxy, C_1 - C_3 -alkylthio eller $-NR^6R^7$,
 20 R^6 og R^7 er hver uafhængigt -H, C_1 - C_3 -alkyl, C_1 - C_3 -alkyl substitueret med hydroxyl, eller C_1 - C_3 -alkyl substitueret med C_1 - C_3 -alkoxy; og den ovennævnte 5-til 6-leddet heterocyclyl er en 5- to 6-leddet heterocyclyl indeholdende 1 til 2 atomer valgt fra gruppen bestående af N, O og S, som er ikke-substitueret, eller er substitueret med C_1 - C_3 -alkyl eller C_1 - C_3 -acyl,
 25 eller er oxideret med 1 til 2 oxygenatomer;
 alternativt,
 hvor R^1 er valgt fra gruppen bestående af en eller flere af de følgende:
 methyl, ethyl, propyl, isopropyl, methoxyethyl, methoxypropyl,
 methoxybutyl, methoxypentyl, methoxyhexyl, tetrahydrofuran-3-yl,
 30 tetrahydro-2H-pyran-4-yl, tetrahydropyrrol-1-ylethyl, tetrahydropyrrol-1-ylpropyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, piperazin-1-ylethyl, piperazin-1-ylpropyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, methylpiperazin-4-ylethyl, methylpiperazin-4-ylpropyl, N-formylpiperazin-4-ylethyl, N-formylpiperazin-4-ylpropyl, N-acetylpiperazin-4-ylethyl, N-acetylpiperazin-4-ylpropyl, (1,1-dioxothiomorpholin)-4-ylethyl, (1,1-
 35

- dioxothiomorpholin)-4-ylpropyl, methylthioethyl, methylthiopropyl, dimethylaminoethyl, dimethylaminopropyl, dimethylaminobutyl, dimethylaminopentyl, dimethylaminohexyl, diethylaminoethyl, diethylaminopropyl, hydroxyethyl, hydroxypropyl, hydroxyethylaminoethyl, hydroxypropylaminoethyl, hydroxyethylaminopropyl, methoxyethylaminoethyl, methoxypropylaminoethyl, methoxyethylaminopropyl, aminoethyl, aminopropyl, aminobutyl, N-methyl-N-hydroxyethylaminoethyl, N-methyl-N-hydroxypropylaminoethyl, N-methyl-N-hydroxyethylaminopropyl, N-methyl-N-methoxyethylaminoethyl, N-methyl-N-methoxypropylaminoethyl, N-methyl-N-methoxyethylaminopropyl, 2-methyl-2-hydroxypropyl, 3-methyl-3-hydroxybutyl, (3S)-3-aminobutyl, (3R)-3-aminobutyl, (3S)-3-hydroxybutyl eller (3R)-3-hydroxybutyl; alternativt,
- 15 hvor R¹ er valgt fra gruppen bestående af butyl, isobutyl, pentyl, isopentyl, hexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, 4,4-dimethylpiperidin-1-ylethyl, 4,4-dimethylpiperidin-1-ylpropyl og oxetan-3-yl.
- 20 **3.** Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge krav 1 eller 2, hvor halogenet beskrevet i R², R³, og R⁴ er Cl eller F.
- 4.** Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge et hvilket som helst af kravene 1-3, hvor R⁵ er -H, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₃-alkyl substitueret med C₃-C₆-cycloalkyl, aryl, C₁-C₃-alkyl substitueret med aryl, heteroaryl eller C₁-C₃-alkyl substitueret med heteroaryl, hvor arylen og heteroarylen er substitueret med en eller flere af de følgende: C₁-C₃-alkyl, C₁-C₃-alkoxy, C₁-C₃-alkylthio, amino
- 25 substitueret med mono- eller di-C₁-C₃-alkyl, halogen, trifluormethyl, aryloxy og methylsulfonyl; og heteroarylen er en monocyklisk eller bicyklisk gruppe indeholdende 1 til 2 heteroatomer valgt fra gruppen bestående af N, O og S, og indeholdende 5 til 10 ringatomer; alternativt,
- 30

hvor R⁵ er valgt fra gruppen bestående af H, methyl, ethyl, propyl,
 isopropyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
 phenyl, 4-fluorphenyl, 3-fluorphenyl, 2-fluorphenyl, 4-chlorphenyl, 3-
 chlorphenyl, 2-chlorphenyl, 2,4-difluorphenyl, 2,5-difluorphenyl, 3,4-
 5 difluorphenyl, 2,4-dichlorphenyl, 2,5-dichlorphenyl, 3,4-dichlorphenyl, 2-
 fluor-4-(trifluormethyl)phenyl, 2-fluor-5-(trifluormethyl)phenyl, 3-fluor-4-
 (trifluormethyl)phenyl, 3-fluor-5-(trifluormethyl)phenyl, 3-(trifluormethyl)-
 4-fluorphenyl, 2-fluor-4-chlorphenyl, 2-fluor-5-chlorphenyl, 3-fluor-4-
 chlorphenyl, 3-fluor-5-chlorphenyl, 3-chlor-4-fluorphenyl, 2-chlor-4-
 10 (trifluormethyl)phenyl, 2-chlor-5-(trifluormethyl)phenyl, 3-chlor-4-
 (trifluormethyl)phenyl, 3-chlor-5-(trifluormethyl)phenyl, 3-(trifluormethyl)-
 4-chlorphenyl, 2-chlor-4-fluorphenyl, 2-chlor-5-fluorphenyl, 3-chlor-4-
 fluorphenyl, benzyl, phenethyl, 4-fluorbenzyl, naphthalen-1-yl, 3-methyl-
 isoxazol-5-yl, 4-phenoxyphenyl, 3-(methylsulfonyl)phenyl, 4-
 15 (methylsulfonyl)phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 3-
 methoxybenzyl eller 4-methoxybenzyl.

5. Forbindelse med formel (I), eller et farmaceutisk acceptabelt salt, en
 enantiomer eller en diastereomer, et hydrat eller et solvat deraf,



20

i formlen (I),


Q er CH;

G er O;

Z er CH;

25

L er valgt fra gruppen bestående af



hvor X er H eller C₁-C₃-alkyl; Y er H eller C₁-C₃-alkyl; n er 0 til 3, og når n er 0, repræsenterer L



- 5 R¹ er C₁-C₆-alkyl substitueret med 1 til 3 substituenten valgt fra gruppen bestående af C₁-C₃-acyl, halogen, trifluormethyl, cyano, -CONH₂, -NR^aR^b og 4- til 7-leddet heteroalicyklisk gruppe, hvor den 4- til 7-leddede heteroalicykliske gruppe er en 4- til 7-leddet heteroalicyklisk gruppe indeholdende 1 til 2 atomer valgt fra gruppen bestående af N, O og S som
- 10 ringatomer, og den 4- til 7-leddede heteroalicykliske gruppe er substitueret med 1 til 3 substituenten valgt fra gruppen bestående af halogen, C₁-C₃-alkyl, hydroxyl, -NH₂ og C₁-C₃-acyl,
- 15 R^a og R^b er hver uafhængigt -H, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-alkyl substitueret med C₁-C₃-alkoxy, C₁-C₆-alkyl substitueret med C₁-C₃-alkylthio, C₁-C₆-alkyl substitueret med substitueret amino eller ikke-substitueret amino, hvor den substituerede amino er substitueret med mono- eller di-C₁-C₃-alkyl;
- 20 R², R³ og R⁴ er hver uafhængigt H, C₁-C₃-alkyl eller halogen;
- R⁵ er -H, C₁-C₉-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-alkyl substitueret med C₃-C₇-cycloalkyl, aryl, C₁-C₆-alkyl substitueret med aryl, heteroaryl eller C₁-C₆-alkyl substitueret med heteroaryl;
- 25 arylen og heteroarylen er ikke-substitueret, eller er substitueret med 1 til 3 substituenten valgt fra gruppen bestående af en eller flere af de følgende: hydroxyl, amino, cyano, C₁-C₃-alkyl, C₁-C₃-alkoxy, C₁-C₃-alkylthio, amino substitueret med mono- eller di-C₁-C₃-alkyl, halogen, trifluormethyl og methylsulfonyl; og
- den ovennævnte heteroaryl er en monocyklisk eller bicyklisk gruppe indeholdende 1 til 3 heteroatomer valgt fra gruppen bestående af N, O og S og indeholdende 5 til 10 ringatomer.

6. Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge krav 5, hvor R^1 er C_1 - C_6 -alkyl

5 substitueret med 1 til 3 substituenten valgt fra gruppen bestående af C_1 - C_3 -acyl, -F, trifluormethyl, cyano, -CONH₂, -NR^aR^b eller 4- til 7-leddet heteroalicyklisk gruppe, hvor den 4- til 7-leddede heteroalicykliske gruppe er en 4- til 7-leddet heteroalicyklisk gruppe indeholdende 1 til 2 atomer valgt fra gruppen bestående af N, O og S som ringatomer, og den 4- til 7-leddede heteroalicykliske gruppe er

10 substitueret med 1 til 3 substituenten valgt fra gruppen bestående af -F, C_1 - C_3 -alkyl, hydroxyl, -NH₂ og C_1 - C_3 -acyl,

R^a og R^b er hver uafhængigt -H, C_1 - C_3 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_3 -alkyl substitueret med C_1 - C_3 -alkoxy, C_1 - C_3 -alkyl substitueret med C_1 - C_3 -alkylthio, C_1 - C_3 -alkyl substitueret med substitueret amino eller ikke-

15 substitueret amino, hvor den substituerede amino er substitueret med mono- eller di- C_1 - C_3 -alkyl;

R^2 , R^3 og R^4 er hver uafhængigt -H, -F eller -Cl;

R^5 er -H, aryl, C_1 - C_3 -alkyl substitueret med aryl, heteroaryl eller C_1 - C_3 -alkyl substitueret med heteroaryl, hvor arylen og heteroarylen er ikke-

20 substitueret, eller er substitueret med 1 til 3 substituenten valgt fra gruppen bestående af en eller flere af de følgende: hydroxyl, amino, cyano, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy, C_1 - C_3 -alkylthio, amino substitueret med mono- eller di- C_1 - C_3 -alkyl, halogen, trifluormethyl og methylsulfonyl; og

heteroarylen er en monocyklisk eller bicyklisk gruppe indeholdende 1 til 2

25 heteroatomer valgt fra gruppen bestående af N, O og S, og indeholdende 5 til 10 ringatomer.


7. Forbindelsen med formel (I), eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge kravene 1-

30 6, hvor det farmaceutisk acceptable salt af forbindelsen er valgt fra gruppen bestående af et eller flere af de følgende salte: hydrochlorid, hydrobromid, hydroiodid, perchlorat, sulfat, nitrat, fosfat, format, acetat, propionat, glycolat, lactat, succinat, maleat, tartrat, malat, citrat, fumarat, gluconat, benzoat, mandelat, methansulfonat, isethionat, benzensulfonat, oxalat, palmitat, 2-


35 naphthalensulfonat, p-toluensulfonat, cyclohexylsulfamat, salicylat, hexonat,

trifluoracetat, aluminiumsalt, calciumsalt, chlorprocainsalt, cholinsalt, diethanolaminsalt, ethylendiaminsalt, lithiumsalt, magnesiumsalt, kaliumsalt, natriumsalt og zinksalt.

- 5 **8.** Fremgangsmåde til fremstilling af forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratat eller solvatet deraf ifølge kravene 1-6, **kendetegnet ved, at** fremgangsmåden inkluderer trinnet at reagere forbindelsen med formel (II') med forbindelsen med formel (III') for at give forbindelsen med formel (I), hvor Q, G, Z, L, R¹, R², R³, R⁴ og R⁵ er som
- 10 defineret i kravene 1-6,



- 9.** Fremgangsmåde til fremstilling af forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratat eller solvatet deraf ifølge kravene 1-6, **kendetegnet ved, at** fremgangsmåden inkluderer trinnet at
- 15 reagere forbindelsen med formel (II') med forbindelsen med formel (III) for at give forbindelsen med formel (I), hvor Q, G, Z, L, R¹, R², R³, R⁴ og R⁵ er som defineret i kravene 1-6,



20

- 10.** Farmaceutisk sammensætning, bestående af forbindelsen med formel (I), eller det farmaceutisk acceptable salt, eller hydratat deraf ifølge kravene 1-6 og farmaceutisk acceptabel/acceptable bærer(e) eller excipients(er); eventuelt
- 25 midler.

11. Forbindelse med formel (I), eller det farmaceutisk acceptable salt, hydratat eller solvatet deraf ifølge et hvilket som helst af kravene 1-6, til anvendelse i

behandlingen af tyrosinkinase VEGFR-2 og/eller c-MET-relaterede sygdomme, hvor sygdommene inkluderer sygdom i fundus oculi, psoriasis, reumatisk arthritis, atherosklerose, lungefibrose, leverfibrose, ikke-småcellet lungekræft, småcellet lungekræft, brystkræft, bugspytkirtelkræft, gliom, glioblastom, 5 æggestokkræft, livmoderhalskræft, kolorektal kræft, melanom, endometriekræft, prostatakræft, blærekræft, leukæmi, gastrisk kræft, leverkræft, gastrointestinal stromal tumor, skjoldbruskkirtelkræft, kronisk myeloid leukæmi, akut myeloid leukæmi, non-Hodgkins lymfom, nasopharyngeal kræft, spiserørskræft, hjernetumor, B-celle og T-celle lymfom, lymfom, multipelt myelom, galdekræft og 10 sarkom og kolangiokarcinom.

12. Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge krav 1, hvor:

15 Q er CH;
G er O;
Z er CH;
L repræsenterer




20 R^1 er C_1 - C_6 -alkyl, eller C_1 - C_6 -alkyl substitueret med 4- til 7-leddet heterocyclyl;
den ovennævnte 4- til 7-leddet heterocyclyl er en 4- til 7-leddet heterocyclyl indeholdende 1 til 2 atomer valgt fra gruppen bestående af N, O og S;
 R^2 er H eller halogen;
25 R^3 er H eller halogen;
 R^4 er H eller halogen;
 R^5 er aryl, hvor arylen er ikke-substitueret, eller substitueret med et eller flere halogen.

30 **13.** Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratet eller solvatet deraf ifølge krav 12, hvor: R^1 er C_1 - C_6 -alkyl, eller C_1 - C_3 -alkyl substitueret med 5- til 6-leddet heterocyclyl, den ovennævnte 5- til 6-leddet heterocyclyl er en 5- til 6-leddet heterocyclyl



indeholdende 1 til 2 atomer valgt fra gruppen bestående af N, O og S.

- 14.** Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratatet eller solvatet deraf ifølge krav 12, hvor: R^1 er valgt fra
- 5 gruppen bestående af en eller flere af de følgende: methyl, ethyl, propyl, isopropyl, tetrahydropyrrol-1-ylethyl, tetrahydropyrrol-1-ylpropyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, piperazin-1-ylethyl, piperazin-1-ylpropyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, methyldpiperazin-4-ylethyl, methyldpiperazin-4-ylpropyl, N-
- 10 acetylpiperazin-4-ylethyl, N-acetylpiperazin-4-ylpropyl, (1,1-dioxothiomorpholin)-4-ylethyl og (1,1-dioxothiomorpholin)-4-ylpropyl.




- 15.** Forbindelsen, eller det farmaceutisk acceptable salt, enantiomeren eller diastereomeren, hydratatet eller solvatet deraf ifølge krav 1 eller krav 5, hvor
- 15 forbindelsen er valgt fra gruppen bestående af:





10




5






10





15




11



5



10



og

